Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
 
The Effects of Contact [CONTACT_253416]/HEV -Filter on Visual Function 
Protocol CR-6480 
Version: 5.0 
 
Date: 12 June 2023 
 
Investigational Products: senofilcon A with new ultraviolet (UV) and high energy visible 
(HEV) light filter  
 
Keywords: Sphere R&D platform, Presby[CONTACT_19555] R&D Platform, Astigmatism R&D Platform, 
ACUVUE  OASYS MAX 1 -Day, ACUVUE  OASYS MAX 1 -Day Multifocal, ACUVUE  
OASYS 1 -DAY, ACUVUE  OASYS Multifocal, ACUVUE  OASYS 1 -Day 
for Astigmatism, senofilcon A, UV/HEV -filter, daily wear, daily disposable, non-dispensing, 
psychometric evaluation, visual range, brightness perception, motion detection.  
 
Statement of Compliance to protocol, GCP and applicable regulatory guidelines: 
This trial will be conducted in compliance with the protocol, ISO [ZIP_CODE]:2020,1 the Declaration 
of Helsinki,2 and all applicable regulatory  requirements. 
 
Confidentiality Statement: 
This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, 
released  or published without written  approval from  [COMPANY_012] Vision  Care,  Inc. The 
information  may not be disclosed  to others except  to the extent  necessary  to obtain Institutional 
Review Board/Independent Ethics Committee approval and informed consent, or as required by [CONTACT_19543], Federal and State Laws, as applicable. Persons to whom this information is disclosed must be informed that this information is  privileged and confidential and that it 
should not be further disclosed without the written permission of [COMPANY_012] Vision Care, Inc. Any supplemental information that may be added to this document is also confidential and proprietary to Johnson &  Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document. 
CR-6480, v5.0
 
Page 1 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
TABLE OF CONTENTS  
SPONSOR NAME  [CONTACT_253462]  ....................................................................................... 6 
MEDICAL  MONITOR  ............................................................................................................. 6 
AUTHORIZED  SIGNATURES  ............................................................................................... 7 
CHANGE  HISTORY  ................................................................................................................ 8 
SYNOPSIS  ................................................................................................................................ 9 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF  TERMS  
................................................................................................................................................. 16 
1. INTRODUCTION AND BACKGROUND .................................................................... 18 
1.1. Name [CONTACT_253463] ................................................ 25 
1.2. Intended Use of  Investigational Products ................................................................. 25 
1.3. Summary of Findings from Nonclinical  Studies ...................................................... 25 
1.4. Summary of Known Risks and Benefits to Human  Subjects  ................................... 25 
1.5. Relevant  Literature  References  and Prior Clinical Data Relevant  to Proposed Clinical 
Study… ............................................................................................................................... [ADDRESS_308277] Articles  ............................................................................................ 33 
CR-6480, v5.0
 
Page 2 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 6.2. Ancillary  Supplies/Products ..................................................................................... [ADDRESS_308278] Articles  ................................................................................ 36 
7. STUDY EVALUATIONS  .............................................................................................. 37 
7.1. Time and  Event Schedule ......................................................................................... 37 
7.2. Detailed  Study Procedures ....................................................................................... 38 
VISIT  1 .............................................................................................................................38 
VISIT  2… .........................................................................................................................49 
FINAL  EVALUATION  .................................................................................................. 57 
7.3. Unscheduled Visits  ................................................................................................... 57 
7.4. Laboratory Procedures ............................................................................................. 59 
8. SUBJECTS COMPLETION/WITHDRAWAL .............................................................. 59 
8.1. Com pletion  Criteria  .................................................................................................. 59 
8.2. Withdrawal/Discontinuation from the Study ........................................................... 59 
9. PRE-STUDY AND CONCOMITANT  INTERVENTION/MEDICATION ................. [ADDRESS_308279]  QUALITY COMPLAINTS  .............. 63 
13. ADVERSE  EVENTS  ................................................................................................... 64 
13.1. Definitions  and Classifications ................................................................................. 64 
13.2. Assessing  Adverse Events ........................................................................................ 67 
13.2.1. Causality  Assessment  .................................................................................... 67 
13.2.2. Severity  Assessment  ...................................................................................... 67 
13.3. Documentation and Follow-Up of Adverse Events ................................................. 68 
13.4. Reporting Adverse Events ........................................................................................ 69 
13.4.1. Reporting Adverse Events to Sponsor .......................................................... 69 
13.4.2. Reporting Adverse Events  to the Responsible IEC/IRB  and Health  Authorities  
………………………………………………………………………………[ADDRESS_308280] .......................................................................................... 70 
13.6.   Reporting of Pregnancy  ............................................................................................ 71 
CR-6480, v5.0
 
Page 3 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 14. STATISTICAL  METHODS  ........................................................................................ [ADDRESS_308281]  KEEPI[INVESTIGATOR_1645]/ARCHIVING  ................................ 75 
15.1. Electronic Case Report  Form/Data  Collection  ......................................................... [ADDRESS_308282]  ......................................................................................................... 76 
15.3. Trial Registration  on ClinicalTrials.gov ................................................................... 76 
16. DATA MANAGEMENT  ............................................................................................. 77 
16.1. Access to  Source Data/Document  ............................................................................ 77 
16.2. Confidentiality  of Information ................................................................................. 77 
16.3. Data Quality Assurance  ............................................................................................ 77 
16.4. Data Monitoring Committee  (DMC)  ........................................................................ [ADDRESS_308283]  (IEC/IRB)  .............. [ADDRESS_308284]  RETENTION  ................................................................................ 81 
20. FINANCIAL  CONSIDERATIONS  ............................................................................ 82 
21. PUBLICATION  ........................................................................................................... 82 
22. REFERENCES  ............................................................................................................ 82 
APPENDIX A: PATIENT REPORTED OUTCOMES  (STUDY QUESTIONNAIRES)  ..... 84 
APPENDIX B: PATIENT  INSTRUCTION  GUIDE  ............................................................. 85 
APPENDIX C: PACKAGE INSERT  (APPROVED PRODUCT)  .........................................  86 
CR-6480, v5.0
 
Page 4 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision  
 APPENDIX D:  ..................................... [ADDRESS_308285] REPORTED  OCULAR  SYMPTOMS/PROBLEMS  ........................ 177 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIVE  
ERROR  ................................................................................................................................. 179 
 BIOMICROSCOPY  SCALE  .............................................................................. 185 
 DISTANCE AND NEAR SNELLEN VISUAL  ACUITY  EVALUATION  ...... 191 
 TOR IC FIT EVALUATION  ............................................................................... 196 
APPENDIX E:  EYE  DOMINANCY  .................................................................................... 201 
APPENDIX F: IRIS  COLOR  SCALE  .................................................................................. 202 
APPENDIX G: GUIDELINES FOR COVID -19 RISK  MITIGATION  .............................. 204 
PROTOCOL COMPLIANCE INVESTIGATOR(S)  SIGNATURE  [CONTACT_1783]  ........................ [ADDRESS_308286] OF TABLES  
Table 1:  Test Articles  .............................................................................................................. 33 
Table 2:  Control Articles  ........................................................................................................ 34 
Table 3:  Ancillary Supplies .................................................................................................... 35 
Table 4:  Sample  Labels  ........................................................................................................... 36 
Table 5: Time and Events:  Phase 1 and Phase 2 .................................................................... 37 
Table 6: Disallowed  systemic  medications  ............................................................................. 61 
Table 7: Disallowed  systemic  antihistamines  ......................................................................... 61 
Table 8: Examples of major and minor protocol deviations ................................................... [ADDRESS_308287] OF FIGURES  
Figure 1: Study Flowchart: Phase 1 ........................................................................................ 14 
Figure 2: Study Flowchart: Phase 2 ........................................................................................ 15 
Figure 3:  Visual range illustration  ......................................................................................... 19 
Figure 4:  Energy of blue haze versus sunlight ....................................................................... 19 
Figure 5:  Wavelength versus relative energy of D6500 illuminant ....................................... 20 
Figure 6:  Schematic of visual range set up  ............................................................................ 20 
Figure 7:  Visual range set up emulates natural  scene  ............................................................ 21 
Figure 8:  Relative Energy of Various Light Sources ............................................................. 22 
Figure 9:  Motion threshold versus stimulus eccentricity  ....................................................... 24 
CR-6480, v5.0
 
Page 5 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 5.[ADDRESS_308288] 
updated sample size.  Based on decision 
from platform leads based on sample size calculations from Phase 1.  
 
Based on decision from platform leads based on sample size calculations from Phase 1.  
 
Based on decision 
from platform leads based on sample size calculations from Phase 1.  
 
Accuracy  
 
 
 
Accuracy  
  12 June 2023  
CR-6480, v5.0
 
Page 9 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
SYNOPSIS  
 
Protocol Title  The Effects  of Contact  [CONTACT_253417]/HEV -Filter  on Visual 
Function  
Sponsor  JJVC, [ADDRESS_308289], Jacksonville, FL  [ZIP_CODE]  
Clinical Phase  Clinical trial phase: Feasibility 
Design control phase: [ADDRESS_308290] Article(s)  Investigational Products: senofilcon A -based contact [CONTACT_13293] 
(toric) with new UV/HEV filter  
Approved Products: ACUVUE  OASYS MAX 1 -Day 
(sphere, multifocal), ACUV UE OASYS 1 -Day (sphere, 
toric), ACUVUE  OASYS Multifocal  
Wear and Replacement  
Schedules  Wear Schedule: Daily wear  
Replacement Schedule: Daily  
Objectives  The objectives of this study are to objectively measure 
potential benefits of a new UV/HEV filter using 
psychophysical testing techniques.  
Study Endpoints  Primary endpoint(s): visual range  
Secondary  endpoint(s): brightness perception, motion 
detection  
Other observations: Ocular physiology . 
Study Design  This is a [ADDRESS_308291] groups (sphere wearers and multifocal wearers) in 
Phase [ADDRESS_308292] groups (sphere wearers, multifocal 
wearers, and toric wearers) in Phase 2. Each subject will be 
bilaterally  fitted  with one of the two test articles  in each of the 
two periods within each study phase.  
 
There will be a total of 2 visits in each phase of the study: 
1. Visit 1: Screening, baseline evaluation, lens fit #1 and psychophysical evaluation  
2. Visit 2: Baseline evaluation, lens fit #2, psychophysical evaluation, and final evaluation. 
 
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main 
observations (Figure 1). 
CR-6480, v5.0
 
Page 10 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
Sample Size  Phase [ADDRESS_308293] 20 to complete ( ∼10 
spherical wearers and ∼10 multifocal wearers). Data from 
Phase 1 will be used for sample size estimation  for Phase 2. 
Subjects in Phase 1 will not participate in Phase  2. 
 
Phase 2 will execute the same procedures as Phase 1 with a 
different sample size. Phase 2 sample size will be calculated 
based on data collected from Phase 1. The total sample size 
for Phase 2 will be approximately 135 subjects  ([ADDRESS_308294] 
group to enroll and 40 to complete)  due to resources and study 
timing.  
Study Duration  There are two study visits in each phase that will last 
approximately 2.5- 3 hours each and will be separated by 1-14 
days. 
• The study enrollment period for Phase 1 will be 
approximately 2 weeks, making the duration of Phase 1 
approximately 4 weeks.  
• Up to 2 weeks will be allotted for statistical analyses.  
• The study enrollment period for Phase 2 will be 
approximately 12 weeks, making the duration of Phase 2 
approximately 14 weeks.  
• The total study  duration  is expected  to last about  [ADDRESS_308295] lenses within the power ranges available for this study: 
 
1. Spherical  
2. Multifo cal 
3. Toric  (astigmatism)  
CR-6480, v5.0
 
Page 11 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
Eligibility Criteria - 
Inclusion Potential subjects must satisfy all of the following criteria to 
be enrolled in the study: 
 
Inclusion Criteria following Screening 
The subject must: 
1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the form.  
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. Be between 18 and 70 (inclusive) years of age at the time of screening. 
4. By [CONTACT_6270]-report,  habitually  wear  soft contact  [CONTACT_13276]  (sphere, 
multifocal, toric) in both eyes in a daily reusable or daily 
disposable wear modality (i.e. not extended wear 
modality). Habitual wear is defined as a minimum of [ADDRESS_308296] 30 days. 
 
Inclusion Criteria at Baseline Evaluation  
5. If applicable, those subjects receiving the spherical lenses will need a vertex -corrected distance refraction within the 
range of -1.00 through -6.00 DS  
6. If applicable , those subjects receiving the multifocal 
lenses will need a vertex -corrected distance refraction 
within the range of - 1.00 through -6.00 DS 
7. If applicable, those subjects receiving the toric lenses  will 
need a vertex -corrected distance refraction within th e 
range of -1.50 through -4.00 DS, -0.625 through 
-1.625 DC, and cylinder axes: 80/90/100, 170/180/[ADDRESS_308297] 
be 20/25 or better in each  eye. 
CR-6480, v5.0
 
Page 12 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
Eligibility Criteria – 
Exclusion Potential subjects who meet any of the following criteria will 
be excluded from participating in the study: 
 
Exclusion Criteria following Screening 
The subject must not: 
1. Be currently pregnant or lactating.  
2. Be currently using any ocular medications or have any 
ocular infection of any type.  
3. By [CONTACT_6270] -report, have any ocular or systemic disease, 
allergies, infection, or use of medication that the 
investigator believes might contraindicate or interfere with contact [CONTACT_13279], or otherwise comp
romise study 
endpoints, including infectious disease (e.g., hepatitis, 
tuberculosis), contagious immunosuppressive disease 
(e.g., Human Immunodeficiency Virus [HIV]), 
autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s 
syndrome), or history of serious mental  illness  or seizures. 
See section 9.[ADDRESS_308298] habitually worn rigid gas permeable (RGP) lenses, 
orthokeratology lenses,  or hybrid lenses  (e.g. SynergEyes, 
SoftPerm) within the past [ADDRESS_308299] 
clinical trial within 14 days prior to study  enrollment.  
7. Be an employee (e.g., Investigator, Coordinator, 
Technician) or immediate family member of an  employee 
(including partner, child, parent, grandparent, grandchild 
or sibling of the employee or their spouse) of the clinical 
site. 
8. (Phase 2 only): Have participated in Phase [ADDRESS_308300] not: 
9. Have clinically significant (grade 3 or higher on the FDA 
grading scale) slit lamp findings (e.g., corneal edema, 
neovascularization or staining, tarsal abnormalities or 
bulbar injection) or other corneal or ocular disease or 
abnormalities that the investi gator believes might 
contraindicate contact [CONTACT_126103] (including entropi[INVESTIGATOR_2394], 
ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of 
recurrent corneal erosions, aphakia, moderate or above 
corneal distortion, he rpetic keratitis).  
10. Have a history of strabismus or  amblyopia.  
CR-6480, v5.0
 
Page 13 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
 11. Have  fluctuations  in vision  due to clinically  significant  dry 
eye or other ocular conditions. 
12. Have had or have planned (within the study period) any 
ocular or intraocular surgery (e.g., radial keratotomy, 
PRK, LASIK, iridotomy, retinal laser photocoagulation, 
etc.).  
Disallowed 
Medications/Interventions No ocular medications. 
See section 9.1 for details regarding disallowed systemic 
medications.  
Measurements and 
Procedures  The new UV/HEV -filter has the potential to provide visual 
benefits that go beyond the correction of ametropia. To 
evaluate some of these benefits,  various laboratory equipment 
will be used to measure visual range, brightness perception, 
and motion detection in accordance with published literature 
and established psychometric and psychophysical  principles.  
Microbiology or Other  
Laboratory Testing  None  
Study Termination  The occurrence of an Unanticipated Adverse Device Effect 
(UADE) or Serious Adverse Event (SAE) for which a causal 
relationship to a test article cannot be ruled out, will result in 
stoppi[INVESTIGATOR_71144]. In the 
event of a UADE or SAE, the Sponsor Medical Monitor may 
unmask the treatment regimen of subject(s) and may discuss 
this with the Principal  Investigator [INVESTIGATOR_253406].  
Ancillary Supplies/ Study - 
Specific Materials  Optical device for measuring visual range; light track for 
motion detection, projected optics for measuring brightness 
perception.  
Principal Investigator(s) 
and Study 
Institution(s)/Site(s)  A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.  
CR-6480, v5.0
 
Page 14 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF 
TERMS  
ADD  Near addition; the additional power required for near vision correction 
ADE  Adverse Device Effect  
ADHD  Attention Deficit Hyperactivity  Disorder 
AE Adverse Event/Adverse Experience 
AO1DfA  ACUVUE OASYS® 1 -DAY with HydraLuxe ™ TECHNOLOGY for 
ASTIGMATISM  
BSCVA  Best Spectacle Corrected Visual Acuity  
CFR  Code of Federal  Regulations 
CLUE  Contact [CONTACT_253418]  
  
D Diopter 
DMC  Data Monitoring Committee  
eCRF  Electronic Case Report  Form  
EDC  Electronic Data Capture 
ESD  Eyelid Stabilized  Design  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice 
HEV  High Energy Visible  
HIPAA  Health Insurance Portability and Accountability Act 
HIV Human Immunodeficiency Virus  
IB Investigator’s Brochure 
ICH The International Council for Harmonization  
IEC Independent Ethics Committee  
IRB Institutional Review  Board  
ISO International Organization for Standardization 
ITT Intent- to-Treat  
JJVC  [COMPANY_012] Vision Care, Inc. 
LASIK  Laser-Assisted in Situ  Keratomileusis  
LRE Log-Relative  Energy 
OD Right Eye 
OS Left Eye 
OU Both Eyes  
PIG Patient Instruction  Guide 
PQC  Product Quality Complaint 
PRK  Photorefractive Keratectomy  
PRO  Patient Reported  Outcome 
QA Quality  Assurance  
SAE  Serious Adverse Event/Serious Adverse Experience  
SAP Statistical Analysis  Plan  
CR-6480, v5.0
 
Page 17 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
SAS Statistical Analysis  System  
SD Standard  Deviation  
UADE  Unanticipated Adverse Device Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
UGA  University of Georgia  
UV Ultraviolet 
VA Visual  Acuity  
CR-6480, v5.0
 
Page 18 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
1. INTRODUCTION AND BACKGROUND 
A. Visibility (a.k.a. visual range, contrast sensitivity function under emulated blue 
haze)  
Bennett in 1930 defined “visibility” as “the clearness with which objects in the atmosphere 
stand out from their surroundings.” In Wooten and Hammond (2012) the authors provided a detailed overview of the atmospherics optics and visual issues that are involved. A few basic ideas were explored:  
 
A.1. Rayleigh’s and Mie’s scatter equations 
Essentially, short -wave (SW) visible light (blue appearing) scatters significantly more than 
other wavelengths. Hence,  a clear  sky is blue, correlating  with the predominance of SW energy 
that is scattered into our eyes. Note that violet wavelengths are scattered more than blue, yet we perceive a blue sky and not a violet sky. This is because the sun emits  more  blue light than 
violet,  and our eyes are more  sensitive  to blue than to violet.  When  particle  diameter  is greater 
than about 0.1λ, Rayleigh’s theory does not explain the scattering. Larger particles scatter more 
and show a more complex spatial pattern and wavelength dependency (smaller particles converge on Rayleigh’s theory, larger, like fog droplets, simpler geometrical optics). 
 
A.2. Haze  aerosols 
Pure air, consisting of only gas molecules, is so rare as to be only of theoretical interest. Ground 
fog is unusual, but not rare. Between these two extremes exists a range of conditions called 
aerosols that constitute the overwhelmingly predomina nt set of factors that largely determine 
the quality of vision in the atmosphere. The wavelength dependency of haze aerosols was first 
presented by [CONTACT_253419] (1952): β sc = cλ-υ. This formula, combined with extensive observations, 
show that scatter  in haze aerosols varies  from  slightly  blue to very blue. 
 
A.3. Visual  range 
Aside from the optical and neural aspects of the human observer, scatter in the aerosol haze  is 
the primary determinant of visual discrimination and range in the outdoors. As we look out 
over the landscape from an elevated location or from an airplane, we notice that the more and more distant elements of the scene become lighter in tone, until sometimes the most distant objects  are indiscernible from  the horizon. Frequently, the scene seems  tinged with a distinctly 
blue hue. Artists call this phenomenon “aerial prospective” and use it as a depth cue in paintings. Atmospheric physicists call it air light. It is this air light that forms a SW  dominant 
veiling illuminance over visual objects in  the distance.  
CR-6480, v5.0
 
Page 19 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Figure 3: Visual range illustration  
 
 
Figure 4: Energy of blue haze versus sunlight 
 
 
A.4. Targets and backgrounds (air light): 
Non-image forming air light acts as a background or veiling luminance with respect to targets 
seen through it. Furthermore, the background luminance increases and becomes increasingly 
short- wave dominant (blue haze)  as the viewing distance increases.  The luminance  of a target, 
on the other hand, decreases and becomes increasingly short -wave deficient as the viewing 
distance increases.  
CR-6480, v5.0
 
Page 20 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Figure 5: Wavelength versus relative energy of D6500 illuminant 
 
 
A short -wave absorbing filter would have a quantitatively different effect on the 
luminance of a background and a target.  A SW filter  would improve contrast for a target  in an 
aerosol haze by [CONTACT_253420] (background) more than the target 
luminance 
 
A.5 The conceptual design of the visibility apparatus: 
In the proposed study, the plan is to use a system that is based on the systems that previously used and published, testing  the ideas  expounded in the Visibility  Hypothesis (Hammond et al., 
2012, Fletcher et al., 2014). 
 
Figure 6: Schematic of visual range set up.  
 
Contrast sensitivity  is measured  using a series  of sine- wave gratings on glass  (back  illuminated 
with broad-band light). Blue Haze is brought in from a different optical channel and imposed 
CR-6480, v5.0
 
Page 21 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
between  the eye and the grating  target.  At the plane of the eye, it can be made to exactly  mimic 
the optics of a natural  scene.  
 
Figure 7: Visual range set up emulates natural scene 
 
 
 
A.6. Details of the method 
The determination of contrast sensitivity requires an apparatus that provides for the careful, 
calibrated variation of sine- wave gratings with respect to spatial frequency and contrast. In 
most vision experiments, these features are achieved with a CRT oscilloscope or computer monitor (or even less precisely, with wall charts like the CSV -1000), which allows relatively 
simple electronic control of both spatial frequency and contrast. However, absolute energy and the spectral energy distributions of the available phosphors are not appropriate for the experiments that we would like to conduct. The need for brighter light in some of the assessments rules out oscilloscopic displays because of their relatively low energy. Also, as noted, we need broad -band light that is close in spectral energy to natural phases of daylight. 
This can be achieved with a combination of integrating spheres and laser light sources; it cannot be done with CRTs. The challenge for our proposal is how to generate and control sine -wave 
gratings in a way that allows a wide range of control of the spectral energy distributions. CRTs, 
computer monitors, wall charts, etc., will not work. Consequently, the previously validated  
apparatus  used in other clinical studies, such as  can be adapted for testing visual 
range under simulated haze conditions, as shown in Figure [ADDRESS_308301] 
with no simulated  haze interposed. The researcher  will gradually introduce haze that increases  
CR-6480, v5.0
 
Page 22 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
The lack of SW energy  in Tungsten- Halogen  would have minimized  any direct  filtering  effects 
in Kelley’s  study. 
 
Details of the method  
The evaluation will involve simple tests of stimulus brightness based on brightness matching: 
in essence, the investigators will set the scene at a moderate brightness and the subject will 
adjust the standard (now the dependent outcome) to match. A projector with a high- intensity 
xenon source will be used to project  natural  scenes  for binocular  viewing. A total of five scenes 
will be selected that vary in their short- mid- and long- wave composition. Participants will 
adjust a neutral density wedge that controls the intensity of a light stimulus presented next to the natural  scene.  The log-relative  energy  at which  the standard  and scene match  to the observer 
will be  recorded.  
 
C. Motion perception (a.k.a. peripheral glare displacement  threshold)  
There are many definitions of motion perception, but some distinctions should be made up front. In past studies we have measured temporal vision (like CFF or the temporal contrast sensitivity function) but this is not motion per se. Motion implies movement across space and typi[INVESTIGATOR_253407]/velocity  and direction. In a real-world  setting,  motion  perception 
also includes input from not just visual but also vestibular and proprioceptive inputs. Most basic motion  experiments  tend to keep  stimulus  exposure (duration) and head  position constant 
while varying the velocity (isochronal thresholds). 
 
The underlying biology of motion perception is well -known and distinct. Retinal ganglion cells 
that act as motion detectors have been identified, as well as the primary visual pathways (primarily  magnocellular) and extrastriate  cortical  areas  specialized  for motion  (like V5). This 
biology itself  could likely  be influenced  by [CONTACT_253421].  For example,  the wavelength 
content of stimuli have been used to bias information transmission down the magno vs the parvocellular pathways. The magnocellular system (unlike parvocellular neurons) does not respond to stimuli varying only in hue. This is the scientific justification behind used colored filters (like Irlen filters) for disorders that reflect parvo -magno imbalances (like dysl exia and 
schizophrenia; although the state of the evidence for using these kinds of filters is pretty controversial; Miyasaka et al., 2019). 
 
Leibowitz et al. (1972) performed the study that was both foundational and is likely the best option for beginning studies in this area. Liebowitz first showed that much of the variance in 
peripheral motion perception is caused by [CONTACT_253422]. The basic result is shown below: 
CR-6480, v5.0
 
Page 24 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Figure 9: Motion threshold versus stimulus eccentri city 
 
 
As shown in the figure, whereas motion thresholds change for all subjects with eccentricity, 
the worsening was much greater for subjects whose refractive condition was not corrected. The  
testing  scheme that Leibowitz  used can be used in this study to emphasize different  optical 
factors (he tested mostly blur) while measuring small changes in isochronal thresholds. 
 
Details of the method  
Leibowitz used only three male graduate students. While a subject maintained monocular fixation with his dominant eye, thresholds for motion perception were determined for the temporal visual field for a one -second exposures at eccentric angles ranging from 0° to 80° in 
10° steps. The stimulus was a white (high reflectance, 80%) square, 1.[ADDRESS_308302] a black (low reflectance, less than one percent) back - 
ground at a distance of 78.7 cm. Subjects report whether the stimuli moved to the left of right (forced choice, with thresholds defined psychometrically). In our applic ation, we will select 
points that are in the area of the curve most affected by [CONTACT_253423] (40- 80 degrees, 
randomly presented). A xenon source will be channeled through a fiber optic light guide affixed to an automated, motor -driven positioning slide that moves left and right on fixed 
increments. Participants will view a centrally located fixation point. The fiber optic test light will be presented  in the periphery. Participants  will judge which direction the test light moved 
from its starting point, either to the left (towards the fixation point) or to the right (away from the fixation point). The essential idea is that the poorer optics results in more aberrated the light,  the less the subject  will be able to correctly  indicate  the direction  of motion. The distance 
necessary for a participant to reliably detect that movement has occurred will be recorded.  
CR-6480, v5.0
 
Page 25 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
1.1. Name [CONTACT_253464] (3) senofilcon A designs (two of which are commercially available: 
ACUVUE OASYS MAX 1 -Day and ACUVUE OASYS MAX 1 -Day Multifocal) that each 
contain a new UV/HEV filter against three (3) commercially available products that don’t 
contain the new UV/HEV -filter (ACUVUE  OAS YS 1 -Day, ACUVUE  OASYS 
Multifocal, and ACUVUE  OASYS 1 -Day for Astigmatism). Further details about the test 
articles are found in Section [ADDRESS_308303] comprehensive nonclinical information  regarding senofilcon A 
lens with new UV/HEV filter, refer to the latest version of the Investigator’s  Brochure.[ADDRESS_308304]  lenses  are well known and are described  in the Investigator’s 
Brochure and Informed Consent. The material safety testing/lens release criteria was determined based on the Risk Assessment. Benefits to the subjects include the correction of their refractive error with the potential of improved contrast in HEV  environments. 
 
For the most comprehensive risk and benefit information  regarding the senofilcon A with new 
UV/HEV- filter, refer to the latest version of the Investigator’s Brochure or the package insert 
of the marketed  products. 
 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed 
Clinical Study  
1. Bennet, MG, 1930. The physical conditions controlling visibility through the 
atmosphere. Quar. J. Roy. Meteorol. Soc. 56, 1–29. 
2. Bovier, E.R., Renzi, L. and Hammond, B.R. (2014). A double -blind, placebo- 
controlled study on the effects  of lutein  and zeaxanthin  on neural  processing  speed  and 
efficiency. PLoS ONE 9(9): e108178. doi:10.1371/journal.pone.0108178. 
3. Fletcher, L. M., Engles, M., & Hammond Jr, B. R. (2014). Visibility through atmospheric haze and its relation to macular pi[INVESTIGATOR_2517]. Optometry and  Vision  Science , 
91(9),  1089-1096. 
4. Gregory, R. L. (2015). Eye and brain: The psychology of seeing. Princeton university 
press.  
5. Hammond, B.R., Warner, R.M. and Fuld, K. (1995). The relationship between blood pressure and sensitivity to flicker. Journal of Psychophysiology, 9(3), 212-220. 
CR-6480, v5.0
 
Page 26 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
6. Hammond Jr, B. R., Wooten, B. R., Engles, M., & Wong, J. C. (2012). The influence 
of filtering  by [CONTACT_253424]. Vision research , 63, 58-62. 
7. Hammond,   B.   R.   (2012).   The   visual   effects   of   intraocular    colored    filters. Scientifica , 2012. 
8. Kelly,  S. A. (1990). Effect  of yellow- tinted  lenses  on brightness. JOSA  A, 7(10),  1905- 
1911. 
9. Leibowitz, H. W., Johnson, C. A., & Isabelle, E. (1972). Peripheral motion detection and refractive error. Science, 177(4055), 1207-1208. 
10. Middleton, WEK, 1952. Vision through the Atmosphere, University of Toronto Press, Toronto, ON,  
11. Miyasaka, J. D. S., Vieira, R. V. G., Novalo-Goto, E. S., Montagna, E., & Wajnsztejn,  
R. (2019). Irlen syndrome: systematic review and level of evidence analysis. Arquivos 
de neuro -psiquiatria , 77(3), 194 -207.  
12. Renzi, L., Bovier. E and Hammond, B.R. (2013). A role for the macular carotenoids in 
visual motor response. Nutritional Neuroscience. 16(6), 262-268. 
13. Wooten, B. R., & Hammond, B. R. (2002). Macular pi[INVESTIGATOR_2517]: influences on visual 
acuity and visibility. Progress in retinal and eye research , 21(2),  225-240. 
 
Additional information about the toric Test lens can be found in the Investigator Brochure. 
Additional information  about the other Test lenses  and the Control lenses  can be found in their 
Package Insert (Appendi x C). 
 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES  
 
2.1. Objectives  
The purpose of this investigation is to evaluate the short -term, clinical psychophysical 
performance of contact [CONTACT_31447] a new UV/HEV -filter.  
 
Primary Objective(s)  
The primary objective of Phase [ADDRESS_308305] clinical data to estimate the required Phase 
2 sample size for achieving the primary objective with adequate statistical power given the prespecified primary hypotheses testing.  The primary objective of the Phase 2 study is to objectively measure potentia l benefits of a 
new UV/HEV filter using psychophysical testing techniques.  
The results from this study may be used to support marketing claims or help understand market 
readiness of the Test lenses that contain the UV/HEV filter.  
 
 
2.2. Endpoints  
The investigational lens has the potential to improve how far the subject can see through blue 
atmospheric haze (visual range), improve how well they can perceive motion, and positively 
influence how bright an image appears compared to the control lens. In this study, the investigators will evaluate these parameters using controlled laboratory systems. 
CR-6480, v5.0
 
Page 27 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Primary Endpoints for Sphere and Multifocal wearers: 
 
1. Visual  Range (tested  binocularly at 8 cycles  per degree).  Visual  range is defined as the 
log relative energy of simulated haze needed to obscure an otherwise high contrast 
grating target. Better visual range is indicated by a higher log- relative energy (LRE) of 
simulated haze (more haze) to obscure an otherwise highly visible target.  
 
Secondary Endpoints: 
 
1. For Spherical wearers - Motion Detection (tested binocularly). Motion detection is 
defined as the distance needed (in mm) to determine that a test light has moved from a 
standard  position. Better  motion detection is  indicated by a smaller distan ce needed to 
detect that movement has  occurred.  
 
2. For Multifocal wearers - Brightness Perception  Score (tested  binocularly). Brightness 
perception  is defined as the log- relative energy needed to match a standard stimulus to 
a natural scene, across 10 different projected  scenes. The perception of brighter image 
is indicated by a higher log- relative energy (LRE) needed to match the initially dim 
standard to the target. The top [ADDRESS_308306].  
 
 
Exploratory Endpoints: 
 
1. For Sphe rical wearers – brightness perception 
2. For Multifocal wearers – motion detection  
3. For Toric wearers – visual range, motion detection, and brightness perception 
4. Biomicroscopy (all contact [CONTACT_19554])  
 
2.2. Hypotheses  
Phase [ADDRESS_308307]  statistically  significantly improved visual 
range than the Control lens among multifocal wearers .  
 
 
CR-6480, v5.0
 
Page 28 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 Secondary Hypotheses - Phase [ADDRESS_308308] satisfy all of the following criteria to be enrolled in the study: 
 
Inclusion Criteria following Screening The subject must: 
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.  
CR-6480, v5.0
 
Page 29 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. Be between 18 and 70 (inclusive) years of age at the time of screening. 
4. By [CONTACT_6270] -report, habitually wear soft contact [CONTACT_35482] a daily reusable or 
daily disposable wear modality (i.e. not extended wear modality). Habitual wear is 
defined as a minimum of [ADDRESS_308309] 30 days. 
 
Inclusion Criteria at Baseline Evaluation  
5. If applicable, those subjects receiving the spherical lenses will need a vertex -corrected 
distance refraction within the range of -1.00 through -6.00 DS 
6. If applicable,  those subjects receiving  the multifocal lenses  will need  a vertex -corrected 
distance refracti on within the range of -1.00 through -6.00 DS 
7. If applicable, those subjects receiving the toric lenses will need a vertex -corrected 
distance refraction  within  the range of -1.50 through -4.00 DS, -0.625 through 
-1.625 DC, and cylinder axes: 80/90/100, 170/180/[ADDRESS_308310] be 20/25 or better in each eye 
 
3.3. Exclusion Criteria  
Potential subjects who meet any of the following criteria will be excluded from participating in the study: 
 
Exclusion Criteria following Screening The subject must not: 
1. Be currently pregnant or lactating.  
2. Be currently using any ocular medications or have any ocular infection of any type. 
3. By [CONTACT_6270] -report, have any ocular or systemic disease, allergies, infection, or use of 
medication that the investigator believes might contraindicate or interfere with  contact 
[CONTACT_13279],  or otherwise compromise study endpoints, including infectious disease (e.g., 
hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), or history of serious mental illness or seizures. See section 
9.[ADDRESS_308311] habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past [ADDRESS_308312] clinical trial within 14 prior to study enrollment.  
7. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family 
member of an employee (including partner, child, parent, grandparent, grandchild or 
sibling of the employee or their spouse) of the clinical site. 
8. (Phase 2 only): Have participated in Phase 1 of the study. 
CR-6480, v5.0
 
Page 30 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Exclusion Criteria at Baseline Evaluation 
The subject must not: 
9. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp 
findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection)  or other corneal  or ocular  disease  or abnormalities  that the investigator 
believes might contraindicate contact [CONTACT_129803] (including entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).  
10. Have a history of strabismus or amblyopia. 
11. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions. 
12. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).  
 
3.4. Enrollment  Strategy  
Study subjects will be recruited from the Institution/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials.  
 
4. STUDY DESIGN AND RATIONALE  
 
4.1. Description of Study  Design  
The study is a 2- phase, single -site, non- dispensing, controlled, randomized, double -masked, 
2x2 crossover (2 study lenses x 2 wearing periods) design where one of the study lenses will be worn bilaterally for 2.5- [ADDRESS_308313] no further access  to the study lenses.  
 
It is important that the subjects wear the same type of lens on both eyes (i.e., both eyes wear spherical,  both eyes wear  multifocal,  or both eyes wear  toric).  All lenses  will be fit for distance 
vision OD and OS according to the fitting guides located in the appendices, which largely follow the Fitting Guide of the control lenses.  
 
Non-presby[CONTACT_35562] (age 18 through 39) may wear either a spherical lens or a toric lens on both 
eyes. The Fitting Guide for spherical products extends to 1.00 D of refractive cylinder, while the Fitting  Guide for toric products starts  at 0.75 D of refractive  cylinder. The investigator will 
therefore use her / his experience in deciding whether the subject will be best fit in a  spherical 
or toric lens on each eye. If fitting the toric lens, the refractive cylinder power should be suitable to be fit with either the 0.75 D or 1.25 D cylinder lens. 
 
Presby[CONTACT_35562] (age 40-70) will be fit with a multifocal lens on both eyes.  Note  that the multifocal 
lenses, particularly the higher ADD powers, are likely to over -refract needing more minus. 
This is normal and will not follow the same 0.00 D over- refraction  requirement  as the spherical 
and toric designs. 
CR-6480, v5.0
 
Page 31 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
4.2. Study Design Rationale 
The purpose of this study is to evaluate the performance of a new UV/HEV -filter in a 2x2 
crossover design for three different subject groups (i.e., sphere wears, multifocal wears, and 
toric wears). Crossover designs are a well -established study design in w hich subjects are 
exposed to multiple treatments during different time periods. This design is cost effective and more efficient since it eliminates part of the inter -subject variability from the treatment 
comparisons. Subjects will be randomized into the two lens wear sequences: Test/Control or Control/Test. Randomization eliminates selection bias and balances both the known and unknown confounding factors that may affect the study outcomes. A potential limitation of crossover design is the carry -over effect from the previous treatment. The 2 study periods 
(visits) will be separated by [ADDRESS_308314] of any previous testing.  
 
• Within  a single measurement  type (e.g., visual range),  a minimum of 30-seconds will 
be taken between  trials.  
• Between measurement types (e.g., when switching from visual range to measuring 
brightness perception), a 5- minute break will be  taken. 
• Participants  will be given a 15- minute  break  after every  [ADDRESS_308315] separated by 1 -14 days. The enrollment period is 12 
weeks making the duration of Phase 2 approximately 14 weeks. If subjects discontinue prior to the final evaluation, then additional subjects may be enrolled at the discretion of the study 
CR-6480, v5.0
 
Page 32 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
sponsor to maintain sample size requirements. The investigation will end at the time that the 
study data is hard locked. 
 
5. TEST ARTICLE ALLOCATION AND MASKING  
 
5.1. Test Article Allocation 
This is a two phase, 2x2 crossover study within each phase. Both study lenses will be worn in a bilateral and randomized fashion. Randomly- permuted block randomization will be used to 
avoid bias in the assignment of subjects to treatment and to enhance the validity of statistical compa risons across treatment groups. A computer -generated randomization scheme will be 
used to randomly assign subjects to one of the two possible lens wear sequences (Test/Control or Control/Test) within each study phase. The randomization will be stratified by [CONTACT_253425].  The random scheme will be generated  by [CONTACT_253426] (SAS) Software Version 9.4 or higher (SAS Institute, Cary, NC).
[ADDRESS_308316] occurred prior to 
randomization: 
 
• Informed consent must have been obtained. 
• The subject must have met all eligibility  criteria.  
• The subject’s screening and baseline information must have been collected.  
5.2. Masking  
This is a double -masked study. Subjects will be unaware of the identity of the investigational 
product. The investigator conducting the psychophysical testing will also not be i nformed. 
Instead, lens type will be identified by [CONTACT_233780], and the link between the code and the lens 
type will not be revealed to the investigator conducting the psychophysical testing until after the database has been locked. The clinician fitting the lenses will not be masked as to the 
identity of the investigational products and may be able to tell the difference between the  Test 
and Control lenses based on color differences between the lenses.  
 
5.3. Procedures for Maintaining and Breaking the Masking  
Ever y attempt will be made to keep the clinical trial personnel involved in the study (e.g. data 
management, study lead biostatistician and clinical operations) unaware of the identity of the assigned study lenses. The identity of the study lenses will be masked by [CONTACT_169761], lot number, sphere power, expi[INVESTIGATOR_35440]. Only the unmasked biostatistician generating the lens fitting schedule will have access  to the decode information  that allows matching  of the randomization  codes  to 
the test articles. The medical monitor will also have access to the decode information in case breaking the mask is necessary for the urgent medical treatment of a subject. 
 
Under normal circumstances, the mask should not be broken until all subjects have completed the study and the database is finalized. Otherwise, the mask should be broken only if specific 
CR-6480, v5.0
 
Page 33 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
• Collect used test article(s) (worn or brought to the visit) from the subjec t and discard 
them, unless otherwise stated in sec tion 7.2. 
• Collect all unused test article(s) from the  subject.  
• Make arrangements for subject care, if needed, due to their study participation 
Additional subjects will be enrolled if a subject discontinues from the study prematurely.  
In cases  where a subject  is lost to  follow-up, every  possible effort  must be made to contact  [CONTACT_93854]/withdrawal. The measures  taken  to follow 
up must be documented including two written attempts and a certified letter (or equivalent)  as 
the final  attempt.  
 
9. PRE -STUDY AND CONCOMITANT  INTERVENTION/MEDICATION 
• Concomitant medications  will be documented during screening  and updated  during the 
study. Disallowed medications for this study include: Any ocular medication. 
medications that may interfere with contact [CONTACT_13279] (see section 9.1). Habitual 
medications used by [CONTACT_253427].  
• Concomitant therapi[INVESTIGATOR_35443]: NA 
9.1. Systemic Medications  
Certain systemic medicat ions are known to have a higher likelihood to interfere with contact 
[CONTACT_13279], chiefly by [CONTACT_35509]. 
 
A summary of disallowed systemic medications is shown in Table 7. Subjects with a history of 
taking these medications will be allowed to enroll only if: 
 
• The medications have been taken on a continual, routine basis for at least 6 months, and 
• The subject has demonstrated successful contact [CONTACT_253428].  
Or: 
 
• The subject was taking the medication on a temporary basis and ceased taking that medication at least 2 weeks prior to signing the informed consent (this is considered sufficient time for the medication to have left the body prior to enrollment).  
 
Subjects with a history of taking medications liste d in Table 6 on a long-term, routine basis 
for less than 6 months will not be allowed to participate in the study. 
CR-6480, v5.0
 
Page 61 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
suspended. Upon review and consultation with IRB, and JJVC Safety Review committee, the 
study may be terminated. 
 
The occurrence of one or more Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE), or any 
SAE where the relationship to study agent cannot be ruled out, may result in stoppi[INVESTIGATOR_253408]. In the event of a [LOCATION_003]DE or SAE, the Sponsor may unmask the 
treatment regimen for the subject(s) and will discuss this with the Investigator before any further subjects are enrolled. 
 
The Sponsor will determine when a study will be stopped. The Principal Investigator [INVESTIGATOR_71152]’s results are compromised. 
 
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The study can be terminated by [CONTACT_079] [INVESTIGATOR_253409], if in their opi[INVESTIGATOR_1649], after a discussion with JJVC,  it is determined 
that it would be unwise to continue at the clinical site. 
 
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unreasonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible. 
 
Should the study be terminated (either prematurely or as scheduled), the Investigator will notify 
the IEC/IRB and Regulatory Authority as required by [CONTACT_35512]. 
 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS  
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges deficiencies related to the identi ty, quality, durability, reliability, safety, 
effectiveness  or performance  of test articles  after they have been  released  for clinical  trial use. 
 
Potential complaints  may come from  a variety  of sources  including but not limited  to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, and site personnel, etc. The following are not considered product quality complaints:  
 
• Subject satisfaction inquiries reported via “Subjective Questionnaires” and “Patient Reported  Outcomes  (PRO).”  
• Clinical test articles that are stored improperly or damaged after receipt at the 
investigational site.  
• Lens replacements that occur due to  drops/fall-outs. 
• Damage deemed by [CONTACT_35513], and 
not indicative  of a quality  deficiency  (i.e. tears,  rips, etc.),  only in situations  where there 
is no deficiency alleged by [CONTACT_423].  
CR-6480, v5.0
 
Page 64 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Within [ADDRESS_308317] be 
recorded in the EDC system, which will trigger an automatic email notification to the 
appropriate COM/CRA  and Clinical QA representative.  In cases  where the EDC  system  in use 
is not configured to send automatic notifications or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
 
Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_253429]: 
 
• Date the complaint was receiv ed/recorded in the EDC System (Date of Sponsor 
Awareness).  
• Who received the complaint. 
• Study number. 
• Clinical site information (contact [CONTACT_2300], site ID, telephone  number). 
• Lot number(s).  
• Unique Subject Identifier(s). 
• Indication of who first observed complaint (site personnel or subject). 
• OD/OS indication, along with whether the lens was inserted.  
• Any related AE number if applicable.  
• Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, resolution of symptoms, etc.).  
• Eye Care Provider objective (slit lamp) findings if applicable.  
• Confirmation  of product availability  for return  (and  tracking  information, if available), 
or rationale  if product is not available for return   
 
 
Once a complaint is received, it will be assessed by [CONTACT_19569], CRA, or trained site personnel to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or trained site personnel will follow se ction 13 of this 
protocol. If the AE/SAE  was potentially  the result  of a product quality  related  deficiency,  these 
procedures also applies and will be executed in parallel.  
 
In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the PQC forms will be marked “Intentionally Left Blank” or “ILB”. Justification for ILB must be documented. 
 
13. ADVERSE  EVENTS  
 
13.1. Definitions and  Classifications  
Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device and whether 
anticipated or unanticipated.” 
CR-6480, v5.0
 
Page 65 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Note : This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. For users or other persons, this definition is 
restricted to events related to investigational medical devices.1 
 
An AE includes any condition (including a pre-existing condition) that: 
 
1. Was not present prior to the study, but appeared or reappeared following initiation of the study. 
2. Was present prior to the study but worsened during the study. This would include any 
condition resulting from concomitant illnesses, reactions to concomitant medications, or progression of disease states.  
 
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event. 
 
Serious Adverse Event (SAE) – An SAE is any adverse event that led to any of the following:  
 
• Death  
• Serious deterioration in the health of the subject that resulted in any of the following: 
• Life-threatening illness or injury 
• Permanent or persistent impairment of a body structure or a body function 
• Hospi[INVESTIGATOR_93790]  
• Medical or surgical intervention to prevent life- threatening illness o r injury or 
permanent impairment to a body structure or a body function. 
• Chronic disease  
• Fetal  distress,  fetal death  or a congenital physical or mental  impairment of birth  defect.  
 
Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to:  
 
• Microbial Keratitis  (MK) 
• Iritis (including cells in the anterior  chamber)  
• Permanent  decrease in best spectacle corrected  visual acuity  equivalent to 2 acuity  lines 
or greater  
• Central Corneal  Opacity  
• Central Corneal  Neovascularization  
• Uveitis  
• Endophthalmitis 
• Hypopyon 
• Hyphemia 
• Penetration of Bowman’s Membrane 
• Persistent Epi[INVESTIGATOR_32958]  
• Limbal cell Damage leading to  Conjunctivalization  
CR-6480, v5.0
 
Page 66 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Significant Adverse Events – are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact [CONTACT_253430], but 
not limited to the following: 
 
• Contact L ens Induced Peripheral Ulcer (CLPU) 
• Significant Infiltrative Events  (SIE)  
• Superior Epi[INVESTIGATOR_32955]  (SEALs)  
• Any Temporary Loss of > 2 Lines of BSCVA  
• Other grade 3 or higher corneal findings, such as abrasions or edema  
• Non-contact [CONTACT_71176] - e.g. Epi[INVESTIGATOR_71155] (EKC)  
• Asymptomatic Corneal Scar 
• Any corneal event which necessitates temporary lens discontinuation > 2 weeks  
 
Non-Significant Adverse Events – are defined as those events that are usually  asymptomatic 
and usually do not warrant discontinuation of contact [CONTACT_35517] a reduction in wear time. However, the Investigator may choose to prescribe treatment as a precautionary measure.  
 
Diagnoses and conditions that are considered  Ocular  Non-Significant Adverse Events include, 
but not limited to the  following: 
 
• Non-significant Infiltrative Event (NSIE)  
• Contact [CONTACT_19573][INVESTIGATOR_19534]  (CLPC)  
• Superficial Punctate Keratitis  (SPK)  
• Conjunctivitis: Bacterial, Viral,  Allergic  
• Blepharitis  
• Meibomianitis  
• Contact  [CONTACT_32984]  
• Localized Allergic  Reactions  
• Any corneal event not explicitly defined as serious or significant adverse event, which necessitates temporary lens discontinuation < [ADDRESS_308318] (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device.”  
NOTE 1: This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device. 
 
NOTE 2: This definition includes any event resulting from use error or from intentional 
misuse of the investigational medical device.[ADDRESS_308319] (UADE) – A UADE is any serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, the 
test 
CR-6480, v5.0
 
Page 67 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
article, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational plan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects.  
 
13.2. Assessing Adverse  Events  
In conjunction with the medical  monitor, the Investigator will evaluate adverse events  to ensure 
the events are categorized correctly. Elements of categorization will  include: 
 
• Seriousness/Classifications (see definition in sec tion 13.1).  
• Causality  or Relatedness  – i.e., the relationship between  the test article,  study treatmen t 
or study procedures and the adverse event (not related, unlikely related, possibly related, or related - see definition in sec tion 13.2.1 ). 
• Adverse Event Severity – Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild, moderate, or severe - see definition in sec tion 
13.2.2).  
• Outcome – not recovered or not resolved, recovering or resolving, recovered or 
resolved with sequelae, recovered or resolved, death related to adverse event, or 
unknown. 
• Actions Taken – none, temporarily discontinued, permanently discontinued, or other. 
13.2.1. Causality Assessment  
Causality Assessment  – A determination  of the relationship  between  an adverse event  and the 
test article. The test article relationship for each adverse event should be determined by [CONTACT_32981]: 
 
• Not Related - An adverse event that is not related to the use of the test article, study 
treatment or study procedures. 
• Unlikely Related – An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is not likely.  
• Possibly Relate d – An adverse event that might be due to the use of the test article, or 
to the study treatment  or study procedures. An alternative  explanation, e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded. 
• Related  – An adverse event that is listed  as a possible adverse effect  (device)  or adverse 
reaction (drug) and cannot be reasonably explained by [CONTACT_4867], e.g. concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by [INVESTIGATOR_5328]- challenge and  re-challenge.  
 
13.2.2. Severity  Assessment  
Severity  Assessment  – A qualitative  assessment  of the degree of intensity  of an adverse event 
as determined by [CONTACT_19577]/her by [CONTACT_423]. The assessment of severity is made irrespective of test article, stud y treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to the following scale:  
CR-6480, v5.0
 
Page 68 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
• Mild – Event is noticeable to the subject but is easily tolerated and does not interfere 
with the subject’s da ily activities.  
• Moderate – Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s daily  activities.  
• Severe – Event is intolerable, necessitates additional therapy or alteration of therapy 
and interferes with the su bject’s daily  activities.  
 
13.3. Documentation and Follow- Up of Adverse Events  
The recording and documenting of adverse events (ocular and non- ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure. Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded  as medical  history. However,  if the condition deteriorates  at any time during the study 
it will be recorded  and reported as an AE. Untoward medic al events  reported after the subject’s 
exit from the study will be recorded as adverse events at the discretion of the Investigator. 
 
Upon finding an adverse event, the Principal Investigator [INVESTIGATOR_253410].  
 
Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic reactions not meeting the criteria for “serious adverse events” shall  be captured  on the appropriate case report form  or electronic  data system. 
All adverse events occurring while the subject is enrolled in the study must be documented appropriately regardless of relationship. 
 
It is the Investigator’s responsibility  to maintain  documentation of each reported  adverse event. 
All adverse events  will be followed in accordance with applicable licensing  requirements.  Such 
documentation will include the following: 
 
• Adverse event (diagnosis not symptom). 
• Drawings or photographs (where appropriate) that detail the finding (e.g., size, location, and depth, etc.).  
• Date the clinical site was  notified. 
• Date and time of  onset. 
• Date and time of  resolution. 
• Adverse event classification, severity, and relationship to test articles, as applicable.  
• Treatment regimen instituted (where appropriate), including concomitant medications prescribed, in accordance with applicable licensing  requirements.  
• Any referral to another health care provider if needed. 
• Outcome, ocular damage (if  any). 
• Likel y etiology. 
• Best corrected visual acuity at the discovery of the event and upon conclusion of the event, if the AE is related to the visual system.  
CR-6480, v5.0
 
Page 69 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Upon discovery of an AE that is deemed ‘possibly related’ or ‘related’ to the test article or 
study procedures (whether  related  to the visual system  or not), an AE review  form   
must be completed. Additional dated and initialed entries should be made at follow -up 
evaluations. Separate forms must be completed for each eye if the AE is  bilateral.  
 
In addition, if an infiltrate(s)  is present,  he/she will complete  the Corneal  Infiltrate  Assessment 
eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be  recorded. 
 
Changes in the severity of an AE shall be documented to allow an assessment of the duration of the event at each level of intensity to be performed. Adverse e vents characterized as 
intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the assessment of relationship to the Test Article shall also be clearly documented.  
 
Subjects who present with an adverse event shall be followed by [CONTACT_737], within licensure, until all signs and symptoms have returned to pre -treatment status, stabilized, or been 
satisfactorily resolved. If further treatment beyond licensure is required, the patient will be referred to the appropriate he alth care provider. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in the study. If 
a subject is discontinued from the study, it will be the responsibility of the Investigator to record the reason for discontinuation. The Investigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events  related  to the test article,  study treatment  or study procedures, as of  the final study visit 
date, should be followed to resolution of the adverse event or until referral to an appropriate health care provider, as recommended by [CONTACT_737]. Non- ocular adverse events that are 
not related to the test article, study treatme nt, or study procedures may be recorded as 
“ongoing” without further follow-up. 
 
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event  by e- mail,  facsimile,  or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant adverse events, and 2 days from discovery for any non- significant adverse event. In addition, 
a written report will be submitted by [CONTACT_253431]/IRB according to 
their requirements (section 13.4.2). The report will comment whethe r the adverse event was 
considered to be related to the test article, study treatment or study procedures.  
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events  
The Investigator will inform the sponsor of all serious/significant adverse events occurring during the study period as soon as possible by e -mail or telephone, but no later than 24 hours 
following discovery of the event. The Investigator is obligated to pursue and obtain information  
requested  by [CONTACT_253432].  All subjects  
experiencing  a serious/significant adverse event  must be followed up and all outcomes must be  
reported. 
CR-6480, v5.0
 
Page 70 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles. 
 
In the event of a serious/significant adverse event, the Investigator must: 
 
• Notify the Sponsor immediately.  
• Obtain and maintain in the subject’s records all pertinent medical information and 
medical judgment for colleagues who assisted in the treatment and follow -up of the 
subject.  
• Provide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test  article.  
• Notify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to national regulations. 
 
Unanticipated (Serious) Adverse Device E ffect (UADE)  
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report  of the UADE  to the Sponsor and IEC/IRB  as soon as possible, but no later 
than [ADDRESS_308320] report the results of the evaluation to FDA, the IEC/IRB and participating Investigators within [ADDRESS_308321]. 
 
Non-Serious Adverse Events  
All non- serious adverse events, including non- serious adverse device effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from discovery. 
 
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the IEC/IRB’s  written  guidelines. Each  clinical  site will refer to and follow any guidelines set forth 
by [CONTACT_19581]/IRB.  Each  clinical  site will refer to and follow any guidelines set forth 
by [CONTACT_19582]. 
 
The Sponsor will report applicable Adverse Events to the local health authorities according to the written guidelines, including reporting timelines. 
 
13.5. Event of Special  Interest  
None 
CR-6480, v5.0
 
Page 71 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
13.6. Reporting of Pregnancy  
Subjects reporting pregnancy (by [CONTACT_6270] -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. On ce discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact [CONTACT_71179], but due to general  concerns relating  to pregnancy and contact  [CONTACT_19584]. Specifically,  pregnant women  are 
discontinued due to fluctuations in refractive  error  and/or visual acuity  that occur  secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.  
 
14. STATISTICAL  METHODS  
 
14.1. General  Considerations 
Statistical Analysis will be undertaken by [CONTACT_35522]. A 
general  description  of the statistical methods to be implemented  in this clinical  trial is outlined 
below. 
 
All data summaries and statistical analyses will be performed using the Statistical Analysis 
System (SAS) software Version 9.4 or higher (SAS Institute, Cary, NC).[ADDRESS_308322]/eye will be used when  available for summarization 
and statistical analysis.  Unscheduled visits  will be summarized  separately  and will be excluded 
from the statistical analysis.  
 
Summary  tables  (descriptive statistics  and/or frequency  tables)  will be provided for all baseline 
variables, efficacy variables and safety variables as appropriate. Continuous variables will be summarized with descriptive statistics (n, mean, standard deviation [SD], median, minimum and maximum). Frequency count and percentage of subjects or eyes within each category will 
be provided for categorical data.  
 
Summaries will be presented separately for each phase and lens type (Test and Control) and will be performed  separately  by [CONTACT_253433]  (Safety  Population, Per-Protocol Population 
and Intent -to-Treat Population, when appropriate).  
 
14.2. Sample Size Justification  
Sample size for Phase 1 was not determined on the basis of  statistical considerations because 
it is primarily for the collecting clinical data to calculate the required sample size for Phase 2 . 
Sample size requirements for Phase 2 were  based on assumptions derived from the analysis of 
selected data collected in Phase 1 . It was calculated that the total sample size of 120 subjects 
to complete (40 per group)  the study provides at least 90% power to test each primary and 
secondary hypothesis. The sample size and power calculations were performed using a paired 
sample  t-test approach (exact method) in PASS (NCSS, 2021).[ADDRESS_308323], in order to propagate the full alpha to the secondary family of hypothesis tests. The Bonferroni approach will apply then to testing the secondary efficacy endpoints. 
CR-6480, v5.0
 
Page 72 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 The sample size estimates for primary endpoints were calculated using 1 -sided T ype I error 
rate of 0.025 for each endpoint . The sample size estimates for the two secondary endpoints 
were adjusted using a Bonferroni adjustment and calculated using a one -sided T ype I error rate 
of 0.0125 ( i.e., one-sided 0.025/2).  
 
While no Toric wearers were enrolled in Phase 1, i t is anticipated  that the multifocal group 
would require  the largest  sample  due to simultaneous optics  of the multifocal lens and the 
intraocular  scattering  that naturally  occurs  with age, which can both compromise and reduce 
the quality of vision. Hence it is expected that the sample size required to test endpoints for 
Toric  wearers would be no more than the sample size required for Multifocal wearers. As these 
endpoints did not have data from Phase 1, all hypotheses for the Toric wearers will be 
exploratory endpoints.   Table [ADDRESS_308324] sizes . Based on the table below, it is planned that Phase 2 will enroll 
approximately 135 subjects (45 subjects per group) with the target of  120 subjects (40 subjects per group) to complete the study, assuming approximately a 10% drop-out rate.   Table 9: Assumptions for Power and Sample Size Calculations for The Primary and Secondary 
Endpoints  
Endpoint 
Type Endpoint 
(Subject 
Group) Standard 
Deviation of 
Paired 
Differences  Effect Size  Alpha  Power  Sample 
Size Per 
Group 
Primary  
 Visual Range 
(Sphere)  0.10 1.83 0.05 0.94 6 
Visual Range 
(Multifocal ) 0.23 0.52 0.05 0.90 41 
Secondary Motion 
Detection 
(Sphere)  1.16 0.99 0.03 0.92 16 
Brightness 
Perception 
(Multifocal ) 0.20 0.70 0.03 0.91 29 
 
14.3. Analysis Populations 
Safety  Population: 
All subjects who are administered any test article excluding subjects who drop out prior to 
administering any test article.  
 
Per-Protocol  (PP)  Population:  
All subjects who successfully complete all visits and do not substantially deviate from the 
protocol as determined by [CONTACT_35524]. Justification for the exclusion of subjects with protocol deviations from the per -protocol 
population set will be documented in a memo to file. 
 
Intent -To-Treat (ITT P opulation):  
All randomized subjects regardless of actual treatment and subsequent withdrawal from the 
study or deviation from the protocol.  
CR-6480, v5.0
 
Page 73 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
 
14.4. Level of Statistical  Significance  
Although the Test and Control lenses are senofilcon A based lenses with and without the new  
UV/HEV filter, respectively, the study lenses assigned to each subject group will be different 
with different optical designs specifically for vision correction of the sphere, multifocal, and toric (astigmatism) lens wearers. Therefore, the planned hypotheses in Phase [ADDRESS_308325]  group. For secondary hypotheses, the Type I error  rate will be adjusted  using the  
Bonferroni approa ch for the two secondary hypotheses and  each  secondary hypothesis will be 
tested using the Bonferroni adjusted one-sided Type I error rate 0.0125 (i.e., one -sided 
0.025/2).   
 
14.5. Primary Analyses  
Phase  [ADDRESS_308326] groups (i.e., 
Spherical wearers and  Multifocal wearers)  using a linear  mixed  model. The analysis  will be 
conducted on the ITT population. An appropriate distribution from the  exponential family 
(e.g., normal  or lognormal) will be considered for the linear mixed modeling based on the 
distribution of the endpoint. The model will include lens type, lens sequence, and period as 
fixed  effects.  Other  baseline and subject  characteristics  such as age, gender, race,  and iris color 
will be included as fixed  covariates  when  appropriate. An unstructured (UN) covariance matrix 
will be used to model the residual errors among within- subject repeated measures (R -side). If 
the model fails to converge, a Compound Symmetric (CS)  matrix may be considered. The 
Kenward and Roger method7 will be used for the denominator degree of freedom.  
 
Hypothesis Testing 
The null and alternative hypotheses for testing superiority of the Test relative to the Control 
with respect to mean visual range within each subject group (Spherical wearers and Multifocal 
wearers) are as follows:  
 
𝐻𝐻0: 𝜇𝜇𝑇𝑇− 𝜇𝜇𝐶𝐶 ≤ 0 
𝐻𝐻𝐴𝐴: 𝜇𝜇𝑇𝑇− 𝜇𝜇𝐶𝐶>  0 
 
Where 𝜇𝜇𝑇𝑇 and 𝜇𝜇𝐶𝐶 represent  mean  visual range (i.e., LRE  of simulated  haze)  for the Test and 
Control lenses, respectively. The one-sided  confidence interval for the least -squares (LS) mean 
difference (Test – Control) and associated p -value will be calculated to test the primary 
CR-6480, v5.0
 
Page 74 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 hypothesis for visual range. Superiority of the Test lens relative  to the Control will be declared 
if the lower confidence limit is greater than  0. 
 
If a significant sequence effect will be  observed, only the period [ADDRESS_308327] at the two study periods (R -side).  If the model fails to 
converge, a CS matrix may be considered. The Kenward and Roger method7 will be used for 
the denominator degree of freedom.  
 
Hypothesis Testing 
The null and alternative hypotheses for testing superiority of the Test relative to the Control 
with respect to mean motion detection within the Spherical wearer subject group are as follows:  
 
𝐻𝐻0: 𝜇𝜇𝑇𝑇− 𝜇𝜇𝐶𝐶 ≥ 0 
𝐻𝐻𝐴𝐴: 𝜇𝜇𝑇𝑇− 𝜇𝜇𝐶𝐶<  0 
 
where 𝜇𝜇𝑇𝑇 and 𝜇𝜇𝐶𝐶 represent mean motion detection (i.e., distance needed to detect that 
movement) for the Test and Control lenses, respectively. The one-sided  adjusted confidence 
interval for the LS mean difference (Test – Control) and associated p -value will be calculated 
to test statistical superiority. Superiority of the Test lens relative to the Control will be declared 
if the adjusted upper confidence limit is less than 0. 
 
Brightness Perception 
The brightness perception (LRE) will be analyzed for the Multifocal wearers   subject group 
only using a linear mixed model. The analysis will be conducted on the ITT population. The model will include lens type, lens sequence, period, and natural scene as fixed effects. Other 
subject characteristics such as age, gender, race, and iris color will be included as fixed 
covariates when appropriate. An UN covariance matrix  will be used to model the residual  errors  
of within -subject  repeated  measures (R -side). If  the model fails to converge, a CS matrix may 
be considered. The Kenward and Roger method
[ADDRESS_308328] group are as 
follows: 
 
𝐻𝐻0: 𝜇𝜇𝑇𝑇− 𝜇𝜇𝐶𝐶 ≤ 0 
𝐻𝐻𝐴𝐴: 𝜇𝜇𝑇𝑇− 𝜇𝜇𝐶𝐶> 0 
CR-6480, v5.0
 
Page 75 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
where 𝜇𝜇𝑇𝑇 and 𝜇𝜇𝐶𝐶 represent mean brightness perception (i.e., LRE) for the Test and Control 
lenses, respectively. The one-sided adjusted confidence interval for the LS mean differ ence 
(Test  – Control) and associated p -value will be calculated to test statistical superiority. 
Superiority of the Test lens relative to the Control will be declared if the adjusted lower 
confidence limit is larger than 0.  
 
If a significant sequence effect was observed, only the period [ADDRESS_308329]  80% power for testing the primary hypothesis within 
each subject group. The total sample size  for Phase [ADDRESS_308330] KEEPI[INVESTIGATOR_1645]/ARCHIVING  
 
CR-6480, v5.0
 
Page 76 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 15.1. Electronic Case Report Form/Data Collection  
The data for this study will be captured  first on a paper  case report  form  (CRF)  to be stored  on 
the study site, so that the investigator conducting the psychophysical testing may perform 
necessary  calculations.  After  calculations  are performed,  the data will be captured  on electronic 
case report forms (eCRFs) using the Clario EDC system. An authorized data originator will enter  study data into the eCRFs  using the EDC  system.  Data collected  on equipment that is not 
captured  in EDC  will be formatted  to the specification  of the JJVC  database manager  and sent 
to JJVC for analysis.  
 
External data sources for this study include: Not Applicable 
 
The clinical  data will be recorded  on dedicated  eCRFs  specifically  designed to match  the study  
 procedures for each visit.  Only  specifically  delegated  staff can enter  data on a CRF.  Once  
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_3786]. The sponsor or sponsor’s representatives will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study. 
 
Edit checks,  electronic queries,  and audit trails  are built into the system  to ensure accurate and 
complete data collection. Data will be transmitted from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and confidentiality.  After  the final  database  lock, the Investigator  will be provided with Individual 
Patient  Profiles  (IPP)  including the full audit trail on electronic media in PDF format  for all of 
the study data.  The IPP must  be retained  in the study  files as a certified  copy of the source data 
for the  study. 
 
The content and structure of the eCRFs are compliant with ISO14155:2020.[ADDRESS_308331] should be available for the following: 
 
• subject  identification  
• eligibility  
• study identification  
• study discussion 
• provision of and date of informed consent 
• visit dates  
• results of safety and efficacy parameters as required by [CONTACT_760] 
• a record of all adverse  events  
• follow-up of adverse events 
• medical history and concomitant medication  
• test article receipt/dispensing/return  records  
• date of study completion  
• reason for early discontinuation of test article or withdrawal from the study, if applicable  
 
The subject record is the eCRF or an external record. The author of an entry in the subject record must be identifiable. The first point of entry is considered to be the source record. 
 
CR-6480, v5.0
 
Page 77 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 Adverse event notes must be reviewed and initialed by [CONTACT_737]. 
 
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by [CONTACT_1034]. 
 
16. DATA MANAGEMENT  
 
16.1. Access to Source Data/Document  
The Investigator/Institution will permit trial- related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the  
 clinical site be contact[CONTACT_35527]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_19592] [ADDRESS_308332] and therefore may disclose it as required to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an obligati on to provide complete test results and all data developed during this study to the 
Sponsor. 
 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of qualified investigators and appropriate clinical sites and review of protocol procedures with the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub- Investigators and clinical site personnel are familiar with the protocol and all study -specific 
procedures and have appropriate knowledge of the study article. 
 
Training on case report form completion will be provided to clinical site personnel before the start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.  
 
Quality Assurance representatives from JJVC may visit clinical sites to r eview data produced 
during the study and to access  compliance with applicable regulations pertaining to the conduct 
of clinical trials. The clinical sites will provide direct access to study -related source 
data/documents and reports for the purpose of monitoring and auditing by [CONTACT_35529].  
 
16.4. Data Monitoring Committee (DMC)  
Not applicable 
 
CR-6480, v5.0
 
Page 78 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 17. CLINICAL  MONITORING  
The study monitors will maintain close contact [CONTACT_35530] [INVESTIGATOR_35453]’s designated clinical site personnel. The monitor’s responsibilities will include: 
 
• Ensuring that the investigation is being conducted according to the protocol, any subsequent versions, and regulatory requirements are maintained. 
• Ensuring the rights and wellbeing of subjects are protected.  
• Ensuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site  personnel. 
• Ensuring that protocol deviations are documented with corrective action plans, as 
applicable.  
 
• Ensuring that the clinical site has sufficient test article and  supplies. 
• Clarifying questions regarding the study. 
• Resolving study issues or problems that may arise.  
• Reviewing of study records and source documentation verification in accordance with 
the m onitoring plan. 
 
18. ETHICAL AND REGULATORY ASPECTS  
 
18.1. Study -Specific Design  Considerations 
Potential subjects  will be fully  informed  of the risks  and requirements  of the study, and, during 
the study, subjects  will be given any new information that may affect  their decision  to continue 
participation.  Subjects  will be told that their consent to participate  in the study is voluntary and 
may be withdrawn at any time with no reason given and without penalty or loss of benefits to which they would otherwise be entitled. Subjects will only be enrolled if the subject is fully able to understand the risks, benefits, and potential adverse events of the study and provide their consent voluntarily.  
 
18.2. Investigator Responsibility  
The Principal Investigator [INVESTIGATOR_253411], the investigational plan, and applicable regulatory requirements. GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance  that the rights, safety,  and well-being 
of study subjects are protected, consistent with the principles of the Declaration of Helsinki [ADDRESS_308333] (IEC/IRB)  
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copi[INVESTIGATOR_23747] (where applicable): 
• Final  protocol. 
• Sponsor-approved informed consent form (and a ny other written materials to be 
provided to the subjects)  
• Investigator’s Brochure (or equivalent information).  
CR-6480, v5.0
 
Page 79 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 • Sponsor-approved subject recruitment materials.  
• Information on compensation for study-related injuries or payment to subjects for 
participation in the  study. 
• Investigator’s curriculum vitae, clinical licenses, or equivalent information (unless  not 
required, as documented by [CONTACT_8134]/IRB).  
• Information regarding funding, name [CONTACT_19618], institutional affiliations, other 
potential conflicts of interest, and incentives for subjects.  
• Any other documents that the IEC/IRB requests to fulfill its  obligation. 
 
This study will be undertaken only after IEC/IRB  has given full approval of the final protocol, 
the informed consent form, applicable recruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of this approval. This approval letter must be   dated and must clearly identify the documents being approved. 
 
During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
 
• Protocol revisions 
• Revision(s) to informed  consent form  and any other written  materials  to be provided to 
subjects  
• If applicable, new or revised subject recruitment materials approved by [CONTACT_1034] 
• Revisions to compensation for study-related injuries or payment to subjects for participation in the  study 
• Investigator’s Brochure revisions 
• Summaries of the status of the study (at least annually or at intervals stipulated in guidelines of the IEC/IRB)  
• Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB’s requirements 
• New infor mation that may adversely affect the safety of the subjects or the conduct of 
the study 
• Major protocol deviations as required by [CONTACT_6179]/IRB  
• Report of deaths of subjects under the Investigator's care 
• Notification if a new Investigator is responsible for the study at the clinical site 
• Any other requirements of the IEC/IRB 
 
For protocol revisions that increase subject  risk, the revisions and applicable informed  consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the  change(s).  
 
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented in writing.
 
 
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this notification  must be retained  at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.  
 
18.4. Informed  Consent  
Each  subject  or their representative,  must give written  consent according to local  requirements 
CR-6480, v5.0
 
Page 80 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 after the nature of the study has  been  fully  explained. The  consent form  must  be signed before 
performance of any study-related activity. The consent form that is used must be approved by 
[CONTACT_19597]/IRB. The informed consent is in accordance with principles that originated in the Declaration of Helsinki,
2 and ISO [ZIP_CODE]:[ADDRESS_308334]'s dated signature. After having obtained the consent, a copy of the informed consent form must be given to the subject.  
 
18.5. Privacy of Personal Data  
The collection, processing and disclosure of personal data and medical information related to 
the Study Subject, and personal data related to Principal Investigator [INVESTIGATOR_71158] (e.g., name, clinic address and phone number, curriculum vitae)  is subject to 
compliance with the Health Information Portability and Accountability Act (HIPAA) in the United  States
[ADDRESS_308335]  these data,  to maintain  the confidentiality 
of the person’s related health and medical information, to properly inform the concerned 
persons about the collection and processing of their personal data, to grant them reasonable access to their personal data and to prevent access by [CONTACT_79778]. 
 
All information  obtained during the course of the investigation  will be regarded  as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by [CONTACT_4718], monitors, Sponsor’s personnel, and IEC/IRB. No data will be disclosed to any third party without the express permission of the subject  concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their investigation related activities that, as part of the investigation will have access to the CRFs and subject records.  
 
The collection and processing of personal data from subjects enrolled in this study will be 
limited  to those data that are necessary  to investigate  the efficacy,  safety,  quality,  and utility  of 
the investigational product(s) used in this study. 
 
These data must be collected  and processed  with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and  regulations. 
The Sponsor ensures that the personal data will be: 
 
• processed fairly and  lawfully.  
• collected f or specified, explicit, and legitimate purposes and not further processed in a 
way incompatible with these  purposes. 
• adequate, relevant, and not excessive in relation to said  purposes. 
• accurate and, where necessary, kept  current.  
CR-6480, v5.0
 
Page 81 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent should also address the transfer of the data to other entities and to other countries. 
 
The subject  has the right to request  through the Investigator access  to his personal  data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps should be taken  to respond to such a request,  taking into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations. 
 
Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or  
 
alteration must be put in place. Sponsor personnel whose responsibilities require access to personal data agree to keep the identity of study subjects confidential.   
19. STUDY RECORD RETENTION  
In compliance with the ISO [ZIP_CODE]:2020,
1 the Investigator/Institution will maintain all CRFs 
and all subject records that support the data coll ected from each subject, as well as all study 
documents as specified in the ISO [ZIP_CODE]:[ZIP_CODE] and all study documents as specified by [CONTACT_12926](s).  The Investigator/Institution  will take measures  to prevent 
accidental or premature destruction of these documents. 
 
Essential documents must be retained  until at least two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontin uation of clinical development of the investigational product. These 
documents will be retained for a longer period if required by [CONTACT_253434]. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained. 
 
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of the name [CONTACT_1640]. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtained written approval from the Sponsor. 
 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any documentation relating to this study, the Investigator must permit access to such reports. If the Investigator has a question regarding retention of study records, he/she should contact 
[CONTACT_19599].  
 
20. FINANCIAL  CONSIDERATIONS  
Remuneration  for study services  and expenses  will be set forth  in detail  in the Clinical Research 
Agreement. The Research Agreement will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC management representative prior to study initiation.  
 
JJVC reserves the right to withhold remuneration for costs associated with protocol violations such as:  
CR-6480, v5.0
 
Page 82 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
 • Continuing an ineligible subject in the study. 
• Scheduling a study visit outside the subject’s acceptable visit range.  
 
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:  
• Query  resolution. 
• Case Report Form  signature. 
• Completion of any follow-up action items.  
 
21. PUBLICATION 
This is a single- site study. The participating  institution  and Principal  Investigator [INVESTIGATOR_253412], should this study  results  be published, the first publication of the results  of this study 
shall be made in conjunction with the presentation of a joint, single -center publication of the 
study results with the investigators and the institutions contributing data, analyses and comments.  
 
22. REFERENCES  
1. ISO [ZIP_CODE]:2020: Clinical investigation of medical devices for human subjects — Good clinical practice,  Available at: https://www.iso.org/standard/[ZIP_CODE].html
 
2. Declaration of Helsinki – Ethical principles for Medical Research Involving Human Subjects,       
Available at: https://www.wma.net/policies -post/wma -declaration -of-helsinki- ethical -principles- for-
medical -research -involving-human- subjects/   
3. [LOCATION_002] (US) Code of Federal Regulations (CFR).  Available at: 
https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR 
4. Buch J.Clinical Study Protocol   Role of glare and spectral  
filtering on contrast sensitivity: A pi[INVESTIGATOR_799] . November 02, 2022  
5. SAS Institute Inc. 2014. SAS/STAT® 13.2 User’s Guide. Cary, NC: SAS Institute Inc. 6. PASS. Power Analysis and Sample Size Software. Kaysville, Utah, [LOCATION_003]: NCSS, LLC; 2021. 7. Kenward MG RJ. Small Sample Inference for Fixed Effects from Restricted Maximum 
Likelihood. Biometrics. 1997;53(3):983. 
8. Health Information Portability and Accountability Act (HIPAA),  Available at: 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html  
CR-6480, v5.0
 
Page 83 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
Not Applicable. 
CR-6480, v5.0
 
Page 84 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
APPENDIX B: PATIENT INSTRUCTION GUIDE  
The Patient Instruction Guide (PIG) will be provided separately. 
CR-6480, v5.0
 
Page 85 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol  
[COMPANY_012] Vision 
   
  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
ACUVUE® OASYS MAX 1 -Day 
ACUVUE® OASYS MAX 1 -Day MULTIFOCAL  
ACUVUE® OASYS 1 -Day with HydraLux e® Technology  
ACUVUE® OASYS 1 -Day with HydraLuxe® Technology for ASTIGMATISM  
ACUVUE® OASYS MULTIFOCAL with PUPIL OPTIMIZED DESIGN  
CR-6480, v5.0
 
Page 86 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
 
 
PACKAGE INSERT & FITTING INSTRUCTION  GUIDE  
 
 
 
 
ACUVUE® OASYS MAX [ADDRESS_308336] Lenses 
ACUVUE® OASYS MAX 1- Day MULTIFOCAL Contact  [CONTACT_253435] A Soft (hydrophilic) Contact [CONTACT_253436]: U.S. Federal law restricts this device to sale by [CONTACT_253437] a licensed practitioner.  
 
IMPORTANT: Please read carefully and keep this information for future use.  
 
This Package Insert and Fitting Guide is intended for the Eye Care Professional, but should be 
made available to patients upon request.  
 
The Eye Care Professional should provide the patient with the appropriate instructions that 
pertain to the patient’s prescribed lenses. Copi[INVESTIGATOR_35461].acuvue.com . 
CR-6480, v5.0
 
Page 87 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
LOW  “Low” near ADD  
MID  “Medium” near ADD  
HGH  “High” near ADD 
Visit www.acuvue.com/guides for additional information about symbols.  
 
 
 
 
 
 
 
  DESCRIPTION   
ACUVUE® OASYS MAX [ADDRESS_308337] Lenses are soft (hydrophilic) contact [CONTACT_253438].  
 
These lenses are made of a silicone hydrogel material (senofilcon A) containing an internal wetting agent 
and are tinted using Reactive Blue Dye #247 to make lenses more visible for handling.  
 
A benzotriazole ultraviolet (UV) absorbing monomer is used to block UV radiation (280 nm – 380 nm) in 
combination with a novel fused tricyclic chromophore that also blocks UV radiation and partially filters 
high energy visible radiation (HEV)* in the range of 380 nm to 450 nm. The light transmittance characteristics for these lenses are less than 1% in the UVB range of 280 nm to 315 nm and 10% in the 
UVA range of [ADDRESS_308338] lenses transmit ≤ 45% of the radiation in the range from 
380 nm to 450 nm. Please see HEV filtering NOTE in the ACTIONS section below.  
 
Lens Properties:  
The physical/optical properties of the lens are:  
 
• Specific  Gravity  (calculated):  0.98 – 1.12  
• Refractive  Index:  1.42  
• Visible  Light  Transmittance:  ≥78%  
• HEV Light Transmittance*:  ≤ 45%  
• Surface  Character:  Hydrophilic  
• Water  Content:  38%  
• Oxygen Permeability  (Dk):  
VALUE  METHOD  
103 x 10-11 (cm2/sec)  
(ml O 2/mL x mm Hg) @ 35°C  Fatt (boundary corrected, edge  
corrected)  
 
Lens Parameter Ranges:  
• Diameter (DIA):  12.0 mm to 15.0  mm 
• Center  Thickness:  varies with  power  
CR-6480, v5.0
 
Page 89 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
• Base Curve (BC):  7.85 mm to 10.00  mm 
• Spherical Power  (D): - 20.00D to  [PHONE_565]D 
• Multifocal ADD  Power:  +0.25D to  +4.00D  
Each lens is supplied in a foil- sealed plastic package containing borate buffered saline solution with 
methyl ether cellulose.  
 
 
 
 
 
 
 
  AVAILABLE LENS PARAMETERS  
 
 
The ACUVUE® OASYS MAX [ADDRESS_308339] Lenses (senofilcon A) are hemispherical shells of the 
following dimensions:  
Diameter (DIA):  14.3 mm 
Center Thickness:  0.085 mm to 0.221 mm (varies with  power)  
Base  Curve (BC):  8.5 mm, 9.0 mm  
Powers (D):  -12.00D to +8.00D  
 
 
The ACUVUE® OASYS MAX [ADDRESS_308340] Lenses (senofilcon A) are hemispherical 
shells of the following dimensions:  
Diameter (DIA):  14.3 mm 
Center Thickness:  0.070 mm to 0.191 mm (varies with  power)  
Base  Curve (BC):  8.4 mm 
Powers  (D): -9.00D to +6.00D  
ADD Powers  (D): +1.25D (LOW), +1.75D (MID), +2.50D  (HGH) 
 
 
  TRANSMITTANCE  CURVE   
ACUVUE® OASYS MAX [ADDRESS_308341] Lenses (senofilcon  A) vs. 24 yr. old human cornea and 25 yr. old 
human crystalline lens.  
CR-6480, v5.0
 
Page 90 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
cloud cover) and personal factors (extent and nature of outdoor activities). UV Blocking contact [CONTACT_253439]. However, clinical studies have not been done to demonstrate that wearing UV Blocking contact [CONTACT_35541][INVESTIGATOR_35457]. The Eye Care Professional should be consulted for more  information.  
 
*NOTE: Filtering of HEV light by [CONTACT_253440], including but not limited to retinal protection, pro tection from cataract 
progression, reduced eye strain, improved contrast, improved acuity, reduced glare, improved low light vision, or improved circadian rhythm/sleep cycle. The Eye Care Professional should be consulted for more information.  
 
  INDICATION S (USES)   
ACUVUE® OASYS MAX [ADDRESS_308342] Lenses (senofilcon A) are indicated for daily disposable wear for the 
correction of vision in people with non -diseased eyes who are nearsighted (myopic) or farsighted 
(hyperopic) and may have 1.00D or less of astigmatism that does not interfere with visual acuity.  
ACUVUE® OASYS MAX [ADDRESS_308343] Lenses (senofilcon A) are indicated for daily 
disposable wear for the correction of vision in people with non -diseased eyes who are presby[CONTACT_253441] (myopic) or farsighted (hyperopic) and may have 0.75D or less of astigmatism that 
does not interfere with visual acuity.  
The lenses are to be prescribed for daily disposable wear. Therefore, no cleaning or disinfection is 
required. Lenses should be discarded upon removal.  
 
 
  CONTRAINDICATIONS (REASONS NOT TO  USE)   
DO NOT USE these lenses when any of the following conditions exist:  
 
• Acute or subacute inflammation or infection of the anterior chamber of the  eye 
• Any eye disease, injury or abnormality that affects the cornea, conjunctiva, or  eyelids  
• Severe insufficiency of lacrimal secretion (dry  eye)  
• Corneal hypoesthesia (reduced corneal sensitivity)  
• Any systemic disease that may affect the eye or be exaggerated by [CONTACT_253442]  
• Ocular irritation due to allergic reactions which may be caused by [CONTACT_253443] (i.e. rewetting drops) that contain chemicals or preservatives (such as mercury or 
Thimerosal, etc.) to which some people may develop an allergic  response 
• Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated  by 
[CONTACT_253442]  
• Any active corneal infection (bacterial, fungal, protozoal, or viral)  
• If eyes become red or  irritated  
CR-6480, v5.0
 
Page 92 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
  WARNINGS   
Patients should be advised of the following warnings pertaining to contact [CONTACT_13279]:  
 
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP RAPI[INVESTIGATOR_253413]. IF THE PATIENT EXPERIENCES:  
 
• Eye Discomfort,  
• Excessive Tearing,  
• Vision  Changes,  
• Loss of Vision,  
• Eye Redness,  or 
• Other Eye  Problems,  
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY REMOVE THE LENSES, AND PROMPTLY CONTACT [CONTACT_35546].  
 
• Patients should be instructed not to wear their lenses while sleepi[INVESTIGATOR_007]. Clinical studies have 
shown that the risk of serious adverse reactions is increased when lenses are worn 
overnight, and that the risk of ulcerative keratitis is greater for extended wear contact [CONTACT_126128].
4 
• Studies have shown that contact [CONTACT_145938] a higher incidence of 
adverse reactions than  nonsmokers. 
• Problems with contact [CONTACT_253444]. 
Patients should be cautioned that proper use and care of contact [CONTACT_253445].  
• The overall risk of ulcerative keratitis may be reduced by [CONTACT_253446].  
4New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773- 783 
 
Specific Instructions for Use and Warnings:  
• Water Activity  
Instruction for Use  
Do not expose contact [CONTACT_35551].  
WARNING:  
 
Water can harbor microorganisms that can lead to severe infection, vision loss, or 
blindness. If lenses have been submersed in water when participating in water sports or 
swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard them and replace them with a new pair. The Eye Care Professional should be consulted for recommendation s regarding wearing lenses during any activity involving water.  
CR-6480, v5.0
 
Page 93 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
  PRECAUTIONS   
 
Special Precautions for Eye Care Professionals:  
• Due to the small number of patients enrolled in clinical investigation of lenses, all refractive 
powers, design configurations, or lens parameters available in the lens material are not 
evaluated in significant numbers. Consequently, when selecting an appropriate lens design 
and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, wettability, central and peripheral thickness, and optic zone  diameter.  
The potential impact of these factors on the patient's ocular health should be carefully 
weighed  against the patient's need for refractive correction; therefore, the continuing 
ocular health of the patient and lens performance on the eye should be carefully monitored by [CONTACT_71187].  
• Patients who wear these lenses to correct presby[CONTACT_253447]. 
Visual requirements vary with the individual and should be considered when selecting the 
most appropriate type of lens for each  patient.  
• Fluorescein, a yellow dye, should not be used while the lenses are on the eyes unless 
otherwise indicated. The lenses absorb this dye and become discolored. Whenever 
fluorescein is used in eyes, the eyes should be flushed with a sterile salin e solution that is 
recommended for in -eye use. 
• Eye Care Professionals should instruct the patient to remove lenses immediately if the eyes become red or  irritated.  
Eye Care Professionals should carefully instruct patients about the following care regimen 
and safety precautions:  
 
Handling Precautions:  
• Before leaving the Eye Care Professional's office, the patient should be able to promptly 
remove lenses or should have someone else available who can remove the lenses for him or 
her. 
• DO NOT use if the  sterile blister package is opened or damaged.  
• Always wash, rinse, and dry hands before handling lenses. It is best to put on lenses before 
putting on  makeup.  
• DO NOT touch contact [CONTACT_253448],  as microscopic scratches of the lenses may occur, causing distorted vision and/or 
injury to the  eye. 
• Carefully follow the handling, insertion, removal, and wearing instructions in the "Patient Instruction Guide" for ACUVUE® OASYS MAX [ADDRESS_308344] Lenses and those prescribed by 
[CONTACT_253449].  
• Always handle lenses carefully and avoid droppi[INVESTIGATOR_35459].  
CR-6480, v5.0
 
Page 94 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
• Never use tweezers or other tools to remove lenses from the lens container. Slide the lens 
up the side of the bowl until it is free of the container.  
 
Lens Wearing Precautions:  
• If the lens sticks (stops moving) on the eye, follow the recommended directions in “Care for 
a Sticking (Non- Moving) Lens” . The lens should move freely on the eye for the continued 
health of the eye. If non -movement of the lens continues, the patient should be instructed 
to immediately consult his or her Eye Care  Professional. 
• Never wear lenses beyond the period recommended by [CONTACT_253449].  
• The patient should be advised to never allow anyone els e to wear their lenses. Sharing 
lenses greatly increases the chance of eye infections.  
• If aerosol products, such as hair spray, are used while wearing lenses, exercise caution and keep eyes closed until the spray has  settled.  
• Avoid all harmful or irritating vapors and fumes while wearing  lenses.  
• Ask the Eye Care Professional about wearing lenses during sporting  activities.  
• The patient should be advised to never rinse the lenses in water from the tap. Tap water contains many impurities that can cont aminate or damage the lenses and may lead to  eye 
infection or injury.  
 
Lens Care Precautions:  
• The patient should be informed that no cleaning or disinfection is needed when lenses are 
worn for daily disposable wear. Patients should always dispose of lenses  when removed and 
have spare lenses or spectacles  available.  
 
Other Topi[INVESTIGATOR_35460]:  
• Always contact [CONTACT_253450].  
• Certain medications, such as antihistamines, decongestants, diuretics, musc le relaxants, 
tranquilizers, and those for motion sickness may cause dryness of the eye, increased lens 
awareness, or blurred vision. Should such conditions exist, proper remedial measures should 
be prescribed. Depending on the severity, this could include  the use of lubricating drops that 
are indicated for use with soft contact [CONTACT_253451].  
• Oral contraceptive users could develop visual changes or changes in lens tolerance when 
using contact [CONTACT_13276]. Patients should be cautioned  accordingly.  
• Do not change lens type (e.g. brand name, etc.) or parameters (e.g. diameter, base curve, lens power, etc.) without consulting the Eye Care  Professional.  
• Instruct patients to al ways confirm the lens parameters printed on the multi -pack and on 
the individual lens package match their prescription. If there is a mismatch the patient should not use the  product.  
CR-6480, v5.0
 
Page 95 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
• As with any contact [CONTACT_13293], follow -up visits are necessary to assure the continuing health of 
the patient’s eyes. The patient should be instructed as to a recommended follow- up 
schedule.  
 
Who Should Know That the Patient is Wearing Contact [CONTACT_32993]?  
• Patients should inform all doctors (Health Care Professio nals) about being a contact [CONTACT_253452].  
• Patients should always inform their employer of being a contact [CONTACT_35560]. Some jobs may 
require use of eye protection equipment or may require that the patient not wear contact 
[CONTACT_13276]. 
  ADVERSE  REACTIONS   
The patient should be informed that the following problems may occur when wearing contact [CONTACT_13276]:  
 
• The eye may burn, sting and/or  itch.  
• There may be less comfort than when the lens was first placed on the  eye. 
• There may be a feeling of something  in the eye (foreign body, scratched  area).  
• There may be the potential for some temporary impairment due to peripheral infiltrates, 
peripheral corneal ulcers, or corneal erosion. There may be the potential for other 
physiological observations, such as loca l or generalized edema, corneal neovascularization, 
corneal staining, injection, tarsal abnormalities, iritis, and conjunctivitis; some of which are clinically acceptable in low  amounts.  
• There may be excessive watering, unusual eye secretions or redness of  the eye. 
• Poor visual acuity, blurred vision, rainbows or halos around objects, photophobia, or dry 
eyes may also occur if the lenses are worn continuously or for too long a  time.  
The patient should be instructed to conduct a simple [ADDRESS_308345] once a day. They 
should ask themselves:  
 
• How do the lenses feel on my  eyes?  
• How do my eyes  look?  
• Have I noticed a change in my  vision?  
If the patient reports any problems, he or she should be instructed to IMMEDIATELY REMOVE THE L ENS. 
If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the 
eye.  
 
If after inserting the new lens, the problem continues, the patient should be directed to IMMEDIATELY REMOVE THE LENS AND CONTACT [CONTACT_35561].  
 
The patient should be advised that when any of the above symptoms occur, a serious condition such as 
infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to  
CR-6480, v5.0
 
Page 96 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
seek immediate professional identification of the problem and prompt treatment to avoid serious eye 
damage.  
 
  GENERAL FITTING  GUIDELINES   
 
A. Patient  Selection  
 
Patients selected to wear these lenses should be chosen based on:  
 
• Motivation to wear  lenses  
• Ability to follow instructions regarding lens wear care  
• General  health  
• Ability to adequately handle and care for the  lenses  
• Ability to understand the risk and benefits of lens  wear  
Patients who do not meet the above criteria should not be provided with contact [CONTACT_13276].  
 
B. Pre- fitting Examination  
 
Initial evaluation of the patient should begin with a thorough case history to determine if there are any 
contraindications to contact [CONTACT_13279]. During the case history, the patient’s visual needs and expectations should be determined as well as an assessment of their overall ocular, physical, and mental 
health.  
 
Preceding the initial selection of trial contact [CONTACT_13276], a comprehensive ocular evaluation should be 
performed that includes, but is not limited to, t he measurement of distance and near visual acuity, 
distance and near refractive prescription (including determining the preferred reading distance for presby[CONTACT_35562]), keratometry, and biomicroscopic evaluation.  
 
Based on this evaluation, if it is determined that the patient is eligible to wear these lenses, the Eye Care 
Professional should proceed to the appropriate lens fitting instruction outlined below.  
 
C. Initial Power Determination 
 
A spectacle refraction should be performed to establish the pat ient’s baseline refractive status and to 
guide in the selection of the appropriate lens power. Remember to compensate for vertex distance if necessary. 
 
D. Base Curve Selection (Trial Lens  Fitting)  
 
The following trial lenses should be selected for patients regardless of keratometry readings. However, corneal curvature measurements should be performed to establish the patient’s baseline ocular status.  
CR-6480, v5.0
 
Page 97 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
For the Spherical or Multifocal ACUVUE® OASYS MAX [ADDRESS_308346] Lenses, the initial lens shou ld be 
selected from the currently available base curves.  
 
The trial lens should be placed on each of the patient’s eyes and evaluated after the patient has 
adjusted to the lenses.  
 
1. Criteria of a Properly Fit  Lens  
 
A properly fit lens will center and completely cover the cornea (i.e., no limbal exposure), have 
sufficient movement to provide tear exchange under the contact [CONTACT_35563], and be 
comfortable. The lens should move freely when manipulated digitally with the lower lid, and then 
return to its properly centered position when released.  
 
2. Criteria of a Flat Fitting Lens  
 
A flat fitting lens may exhibit one or more of the following characteristics: decentration, 
incomplete corneal coverage (i.e., limbal exp osure), excessive movement with the blink, and/or 
edge standoff. If the lens is judged to be flat fitting, it should not be dispensed to the patient.  
 
3. Criteria of a Steep Fitting Lens  
 
A steep fitting lens may exhibit one or more of the following characteristics: insufficient movement with the blink, conjunctival indentation, and resistance when pushing the lens up 
digitally with the lower lid. If the lens is judged to be steep fitting, it should not be dispensed to 
the patient.  
 
If the initial base curve is judged to be flat or steep fitting, the alternate base curve, if available, should be trial fit and evaluated after the patient has adjusted to the lens. The lens should move freely when 
manipulated digitally with lower lid, and then return to a properly centered position when released. If 
resistance is encountered when pushing the lens up, the lens is fitting tightly and should not be 
dispensed to the patient.  
 
E. Final Lens  Power  
 
A spherical over- refraction should be performed to determine the final lens power after the lens fit is 
judged acceptable. The spherical over -refraction should be combined with the trial lens power to 
determine the final lens prescription. The patient should experience good visual acuity with the correct lens power unless  there is excessive residual astigmatism.  
 
Example 1:  
Diagnostic lens:  -2.00D  
 Spherical over -refraction:  -0.25D  
 Final lens power:  -2.25D  
 
Example 2:  
CR-6480, v5.0
 
Page 98 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
Diagnostic lens:  -2.00D  
 Spherical over -refraction:  +0.25D  
 Final lens power:  -1.75D  
If vision is acceptable, perform a slit lamp examination to assess adequate fit (centration and 
movement). If fit is acceptable, dispense the lenses instructing the patient to return in one week for 
reassessment (see dispensing and follow up  information in PATIENT MANAGEMENT ). 
 
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. 
Copi[INVESTIGATOR_253414].acuvue.com . 
 
  MULTIFOCAL FITTING  GUIDELINE S  
 
A. Presby[CONTACT_253453] & Patient Education  
Multifocal contact [CONTACT_253454] (i.e., 
read ing a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). Therefore, 
caution should be exercised when the patient is wearing the correction for the first time until they 
are familiar with the vision provided in visually challenging  environments. Occupational and 
environmental visual demands should be considered. If the patient requires critical visual acuity and stereopsis, it should be determined by [CONTACT_253455]
® OASYS MAX [ADDRESS_308347] Lenses. Wear may not be optimal for such activities 
as: 
1. Visually demanding situations such as operating potentially dangerous machinery or performing 
other potentially hazardous activities;  and 
2. Driving automobiles (e.g., driving at night). Patients who cannot pass their state driver’s license requirements with these lenses should be advised to not drive with this correction, OR may 
require that additional over-correction be  prescribed.  
These lenses are not recommended for patients who ha ve –1.00D or greater of refractive cylinder as 
this level of uncorrected cylinder may lead to additional visual compromise.  
These lenses are available in the following ADD powers:  
• 
Lens “LOW” =“low” near ADD lens (Max +1.25  ADD)  
• Lens “MID” = “medium” near ADD lens (Max +1.75  ADD)  
• Lens “HGH” = “high” near ADD lens (Max +2.50  ADD)  
 
B. Initial Power Determination 
A spectacle refraction should be performed to establish the patient’s baseline refractive status and 
to guide in the selection of the appropriate lens power. Remember to compensate for vertex distance if the refraction is ≥ ±4.00D. Determine the spherical equivalent distance prescription for a multifocal patient. Determine the eye dominance using one of the methods below:  
Method 1:  Determine which eye is the “sighting eye.” Have the patient point to an object at the 
far end of the room. Cover one eye. If the patient is still pointing directly at the object, the eye 
being used is the dominant (sighting) eye.  
CR-6480, v5.0
 
Page 99 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
 
Method 2 (preferr ed): Determine which eye will accept the added power with the least 
reduction in vision while both eyes are open. Place a hand -held trial lens equal to +1.00D in 
front of one eye and then the other while the distance refractive error correction is in place  for 
both eyes. Determine whether the patient functions best with the +1.00D lens over the right or 
left eye, which is the non -dominant eye.  
 
C. Select the Initial Trial Lens  
1. For each eye, select the trial lens distance power that is closest to the patient’s distance 
spherical equivalent. Remember to compensate for vertex distance if the refraction is ≥ ±4.00D.  
2. Select the near power of the lens based on the patients ADD range as  follows:  
• ADD: +0.75 to +1.25 use a “LOW” near ADD lens on each  eye 
• ADD: +1.50 to +1.75 use a “MID” near ADD lens on each  eye 
• ADD: +2.00 to +2.50 use a “MID” near ADD on the dominant eye and a “HGH” near ADD lens on the non -dominant  eye 
3. Allow the lenses to settle for a minimum 10  minutes.  
4. Assess distance and near vision binocularly and  monocularly.  
5. Demonstrate the vision under various lighting conditions (normal and decreased illumination) and at distance, intermediate and  near.  
6. Make adjustments  in power as necessary based on the distance over -refraction. The use of 
hand held trial lenses is recommended. Check the impact on distance and near  vision.  
7. If vision is still unacceptable, make adjustments in power as necessary (see “Multifocal 
Troubleshooting” below). If distance and near vision are acceptable, perform a slit lamp examination to assess adequate fit (centration and movement). If fit is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see PATI ENT 
MANAGEMENT section).  
D. Multifocal Troubleshooting 
Unacceptable Near  Vision: 
If it has been determined that no change is required based on the over -refraction then add +0.25 D 
to the spherical power of the non -dominant eye.  
 
Unacceptable Distance Vision: 
If it has been determined that no change is required based on the over -refraction then make the 
changes as listed below:  
• If the patient is wearing two “LOW” ADD lenses, change the dominant eye to an 
ACUVUE® OASYS MAX [ADDRESS_308348] Lens sphere lens with a power equal to the spherical 
equivalent distance  prescription.  
• If the patient is wearing two “MID” ADD lenses, change the ADD power in the dominant eye 
to the “LOW” ADD  power.  
CR-6480, v5.0
 
Page 100 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
• If the patient is wearing a “MID” ADD lens in the dominant eye and a “HGH” ADD lens in the 
non-dominant eye, change the non -dominant eye to a “MID” ADD lens and add +0.25D to 
the distance  power.  
 
Once the changes have been made for the troubleshooting repeat step s 3-6 in section C above 
(“Select the Initial Trial Lens”) to assess if the vision is acceptable.  
 
E. Adaptation 
Visually demanding situations should be avoided during the initial wearing period. A patient may at first experience some mild blurred vision, dizziness, headaches and a feeling of slight imbalance. You should explain the adaptational symptoms to the patie nt. These symptoms may last for a brief 
minute or for several weeks. The longer these symptoms persist, the poorer the prognosis for successful adaptation.  
To help in the adaptation process, the patient can be advised to first use the lenses in a comfortab le 
familiar environment such as in the home.  
Some patients feel that automobile driving performance may not be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor vehicle, it may be recommended tha t the patient be a passenger first to make sure that their vision is satisfactory for 
operating an automobile. During the first several weeks of wear (when adaptation is occurring), it 
may be advisable for the patient to only drive during optimal driving c onditions. After adaptation 
and success with these activities, the patient should be able to drive under other conditions with 
caution.  
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. 
Copi[INVESTIGATOR_253414].acuvue.com
. 
 
  MONOVISION FITTING GUIDELINES  
 
A. Patient Selection 
Monovision Needs  Assessment  
For a good prognosis the patient should have adequately corrected distance and near visual acuity in 
each eye. The amblyopic patient with significant amounts of uncorrected astigmatism (greater than 
1.00D) in one eye may not be a good candidate for monovision correction with these lenses.  
 
Occupational and environmental visual demands should be considered. If the patient requires critical vision (visual acuity and stereopsis), it should be determined by [CONTACT_71190]. Monovision  contact [CONTACT_253456]:  
 
(1) visually demanding situations such as operating potentially dangerous machinery or 
performing other potentially hazardous activities;  and 
CR-6480, v5.0
 
Page 101 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
(2) driving automobiles (e.g., driving at night). Patients who cannot pass their state driver’s 
license requirements with monovision correction should be advised to not drive with this 
correction, OR may require that additional over- correction be  prescribed.  
 
Patient Education 
 
All patients do not  function equally well with monovision correction. Patients may not perform as well 
for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, progressives). Each patient should understand that monovision, as well as other presby[CONTACT_35569], can create a vision compromise that may reduce visual acuity and depth perception for distance and 
near tasks. Therefore, caution should be exercised. During the fitting process, it is necessary for the 
patient to realize the disadvantages as well as the advantages of clear near vision, and straight ahead and upward gaze that monovision contact [CONTACT_35570].  
 
B. Eye Selection  
 
Generally, the non -dominant eye is corrected for near vision. The following two methods for eye 
dominance can be used.  
 
1. Ocular Preference Determination Methods  
 
Method  1: Determine which eye is the “sighting eye.” Have the patient point to an object at 
the far end of the room. Cover one eye. If the patient is still pointing directly at 
the object, the eye being used is the dominant (sighting) eye. 
 
Method  2: Determine which eye will accept the added power with the least reduction in 
vision. Place a hand- held trial lens equal to the spectacle near ADD in front of 
one eye and then the ot her while the distance refractive error correction is in 
place for both eyes. Determine whether the patient functions best with the near 
ADD lens over the right or left eye 
Other methods include the “Refractive Error Method” and the “Visual Demands Method. ” 
 
2. Refractive Error  Method  
 
For anisometropic correction, it is generally best to fit the more hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.  
 
3. Visual Demands  Method  
 
Consider the patient’s occupation during the eye selection process to det ermine the critical 
vision requirements. If a patient’s gaze for near tasks is usually in one direction, correct the eye on that side for near.  
 
Example:  
CR-6480, v5.0
 
Page 102 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
A secretary who places copy to the left side of the desk will function best with the near lens on 
the left eye.  
 
C. Special Fitting Characteristics  
 
1. Unilateral Vision Correction Requirement  
 
There are circumstances where only one contact [CONTACT_35571]. As an example, an emmetropic 
patient would only require a near lens whereas a bilateral myope would require corrective lenses on both  eyes.  
 
Example:  
 
A presby[CONTACT_35572] a +1.75D ADD would have a +1.75D lens on the near eye and the other eye left without correction.  
 
A presby[CONTACT_35573] a +1.50D ADD who is -2.50D myopic in the right eye and -1.50D 
myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.  
 
2. Near ADD Determination 
 
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient’s habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.  
 
3. Trial Lens  Fitting  
 
A trial fitting is performed i n the office to allow the patient to experience monovision correction. 
Lenses are fit according to the “General Fitting Guidelines” for base curve selection described in 
this guide.  
 
Case history and standard clinical evaluation procedure should be used to determine the prognosis. Determine the distance correction and the near correction. Next determine the near 
ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.  
 
Allow the lenses to settle for about [ADDRESS_308349] the patient look at you. Assess the patient’s reaction to distance 
vision under these circumstances. Then have the patient look at familiar near objects such as a 
watch face o r fingernails. Again assess the reaction. As the patient continues to look around the 
room at both near and distance objects, observe the reactions. Only after these vision tests are 
completed should the patient be asked to read print. Evaluate the patient’s reaction to large 
print (e.g., typewritten copy) at first and then graduate to news print and finally smaller type sizes. 
CR-6480, v5.0
 
Page 103 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
After the patient’s performance under the above conditions is completed, tests of visual acuity 
and reading ability under conditions of moderately dim illumination should be attempted.  
 
An initial unfavorable response in the office, while indicative of a guarded prognosis, should not 
immediately rule out a more extensive trial under the usual conditions in which  a patient 
functions.  
 
4. Adaptation 
 
Visually demanding situations should be avoided during the initial wearing period. A patient may at first experience some mild blurred vision, dizziness, headaches and a feeling of slight imbalance. You should explain the  adaptation symptoms to the patient. These symptoms may 
last for a brief minute or for several weeks. The longer these symptoms persist, the poorer the prognosis for successful  adaptation.  
 
To help in the adaptation process, the patient can be advised to first use the lenses in a comfortable familiar environment such as in the home.  
 
Some patients feel that automobile driving performance may not be optimal during the adaptation process. This is particularly true when driving at night. Before driving a motor 
vehicle, it may be recommended that the patient be a passenger first to make sure that their 
vision is satisfactory for operating an automobile. During the first several weeks of wear (when adaptation is occurring), it may be advisable for the patient to only drive during optimal driving 
conditions. After adaptation and success with these activities, the patient should be able to 
drive under other conditions with caution.  
 
5. Other Suggestions  
 
The success of the monovision technique may be further improved by [CONTACT_253457]:  
 Have a third contact [CONTACT_13293] (distance power) to use when critical distance viewing is  needed.  
 Have a third contact [CONTACT_13293] (near power) to use when critical near viewing is  needed.  
 Having supplementa l spectacles to wear over the monovision contact [CONTACT_253458].  This is particularly  applicable 
for those patients who cannot meet their state driver’s license requirements with a 
monovision  correction.  
 Make use of proper illumination when carrying out visual tasks. 
Monovision fitting success can be improved with the following  suggestions: 
 Reverse the distance and near eyes if a patient is having trouble  adapting.  
 Refine the lens po wers if there is trouble with adaptation. Accurate lens power is critical for 
presby[CONTACT_93931].  
CR-6480, v5.0
 
Page 104 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
 Emphasize the benefits of clear near vision and straight -ahead and upward gaze with 
monovision.  
The decision to fit a patient with monovision correction is most appropriately left to the Eye Care 
Professional in conjunction with the patient after carefully considering the patient’s needs.  
 
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. 
Copi[INVESTIGATOR_253414].acuvue.com . 
 
  PATIENT  MANAGEMENT   
 
• Follow the accepted standard of care in fitting and following up with your  patient.  
• Schedule the appropriate follow -up examination.  
• Preferably, at the follow -up visits, lenses should have been worn for at least six  hours.  
• Provide the patient with a copy of the PATIENT INSTRUCTION GUIDE for these lenses, which can be found at  www.acuvue.com
. REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT 
HE OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT SCHEDULE (DAILY  DISPOSABLE). 
 
  WEARING  SCHEDULE   
 
The wearing schedule should be determined by [CONTACT_35578]. Regular checkups, as 
determined by [CONTACT_35578], are also extremely important.  
 
Patients tend to over wear the lenses initially. The Eye Care Professional should emphasize the 
importance of adhering to the initial maximum wearing schedule. Maximum wearing time should be 
determined by [CONTACT_35579]’s physiological eye condition, because individual response to contact [CONTACT_253459] s. 
 
The maximum suggested wearing time for these lenses is:  
 
Day Hours  
1 6-8 
2 8-10 
3 10-12 
4 12-14 
5 and after  all waking hours  
 
 
  REPLACEMENT  SCHEDULE   
 
These lenses are indicated for daily disposable wear and should be discarded upon removal.  
CR-6480, v5.0
 
Page 105 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
  LENS CARE  DIRECTIONS   
 
When lenses are dispensed, the Eye Care Professional should provide the patient with appropriate and 
adequate warnings and instructions for daily disposable lens wear.  
 
The Eye Care Professional should review with patients that no cleaning or disinfection is needed with 
disposable lenses. Patients should always dispose of lenses when they are removed and have spare lenses or spectacles available.  
 
Basic Instructions: 
• Always wash, rins e, and dry hands before handling contact  [CONTACT_13276]. 
• Do not use saliva or anything other than the recommended solutions for lubricating or rewetting 
lenses. Do not put lenses in the  mouth.  
• Eye Care Professionals may recommend a lubricating/rewetting solution w hich can be used to 
wet (lubricate) lenses while they are being worn to make them more comfortable.  
 
Care for a Sticking (Non -Moving) Lens  
During removal, if the lens sticks to the eye, the patient should be instructed to apply a few drops of the 
recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to 
move freely on the eye before removing it. If non -movement of the lens continues after a few minutes, 
the patient should immediately consult the Eye Care Pr ofessional.  
 
 
 
 
 
 
 
  EMERGENCIES   
 
The patient should be informed that if chemicals of any kind (household products, gardening solutions, 
laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY 
WITH TAP WATER AND IMMEDIATELY CONTACT [CONTACT_35581] A HOSPI[INVESTIGATOR_35466].  
 
  REPORTING OF ADVERSE  REACTIONS   
 
All serious adverse experiences and adverse reactions observed in patients wearing these lenses or 
experienced with the lenses should be reported to:  
 
[COMPANY_012] Vision Care, Inc.  
[ADDRESS_308350]  
Jacksonville, FL [ZIP_CODE] 
[LOCATION_003] 
CR-6480, v5.0
 
Page 106 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 
 
Tel: 1 -[PHONE_5274]  
www.acuvue.com  
 
Revision Date: 02/2022 
Revision Number: AO -01-22-03 
CR-6480, v5.0
 
Page 107 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
 DETERMINATIO N OF NEAR ADDITION 
CR-6480, v5.0
 
Page 165 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Near Addition  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
 
  
 
 
 
 
 
 
CR-6480, v5.0
 
Page 166 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Near Addition  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
CR-6480, v5.0
 
Page 167 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Near Addition  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
 
 
 
 
 
 
CR-6480, v5.0
 
Page 168 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Near Addition  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
 
 
 
  
  
CR-6480, v5.0
 
Page 169 of 216
JJVC CONFIDENTIAL

 
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 LENS FITTI NG CHARACTERISTICS  
CR-6480, v5.0
 
Page 171 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Lens Fitting Characteristics  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6480, v5.0
 
Page 173 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Lens Fitting Characteristics  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 6 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CR-6480, v5.0
 
Page 174 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Lens Fitting Characteristics  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 6 
 
CR-6480, v5.0
 
Page 176 of 216
JJVC CONFIDENTIAL

 
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 SUBJECT REPO RTED OCULAR SYMPTOMS/PROBLEMS  
CR-6480, v5.0
 
Page 177 of 216
JJVC CONFIDENTIAL

 
 Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Title:  Subject Reported Ocular  Symptoms/Problems  
 
Document  Type:   
 
Document Number:   Revision Number: 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6480, v5.0
 
Page 178 of 216
JJVC CONFIDENTIAL

 
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DETERMINATIO N OF DISTANCE  SPHEROCYLINDRICAL 
REFRACTIVE  ERROR 
CR-6480, v5.0
 
Page 179 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Distance Spherocylindrical Refractive Error  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
 
  
 
 
 
 
CR-6480, v5.0
 
Page 180 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Distance Spherocylindrical Refractive Error  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
CR-6480, v5.0
 
Page 181 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Distance Spherocylindrical Refractive Error  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
 
 
 
 
 
CR-6480, v5.0
 
Page 182 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Determination of Distance Spherocylindrical Refractive Error  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
CR-6480, v5.0
 
Page 184 of 216
JJVC CONFIDENTIAL

CR6480, v 3.0  JJVC CONFIDENTIAL   
Page 185 of 216  
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 BIOMICROSCOP Y SCALE  
CR-6480, v5.0
 
Page 185 of 216
JJVC CONFIDENTIAL

 
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 DISTANCE AND NEAR SNEL LEN VISUAL ACUITY EVALUATION 
CR-6480, v5.0
 
Page 191 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Distance and Near Snellen Visual Acuity Evaluation  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
 
 
CR-6480, v5.0
 
Page 193 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Distance and Near Snellen Visual Acuity Evaluation  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 5 
 
CR-6480, v5.0
 
Page 195 of 216
JJVC CONFIDENTIAL

 
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 TORIC FIT E VALUATION 
CR-6480, v5.0
 
Page 196 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Toric Fit Evaluation  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 7 
 
 
CR-6480, v5.0
 
Page 198 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Toric Fit Evaluation  Title:   
 Document  Type:   
 
Document Number:   Revision Number: 7 
 
 
 
 
 
CR-6480, v5.0
 
Page 200 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
APPENDIX F: IRIS COLOR SCALE  
CR-6480, v5.0
 
Page 202 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.   
  
APPENDIX G: GUIDELINES FOR COVID- 19 RISK MITIGATION  
CR-6480, v5.0
 
Page 204 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: 5 
 
 
 
1.0 PURPOSE 
 
The purpose of this document is to provide guidelines for the re -opening or initiation of clinical study sites 
participating in [COMPANY_012] Vision Care, Inc. (JJVCI) clinical studies during the COVID- 19 pandemic.  
 
2.0 SCOPE 
 
This document  provides  guidelines  for Johnson  & Johnson  Vision  Care  (JJVCI)  to address  the potential  risks 
from COVID -[ADDRESS_308351] from the date of approval through the da te of retirement of this Work 
Instruction. At a minimum, this Work Instruction will be reviewed and updated on a quarterly basis, as 
appropriate.  
 
NOTE: Re -opening of sites outside of the US will be evaluated on a country by [CONTACT_253460].  
 
3.0 DEFINITIONS 
 
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, [LOCATION_012]. Its goal is to maintain and enhance excellence in optometric 
practice, by [CONTACT_93949]. The AAO holds an annual 
meeting, publishes a monthly scientific journal, gives credentials to optometrists through the fellowship process and publishes position statements.  
 
American Optometric Association (AOA): The American Optometric Association, founded in 1898, is the 
leading authority on quality care and an advocate for our nation's health, representing more than 44,000 Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take a leading role in patient care with respect to eye and vision care, as well as general health and well -
being. As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, dia gnose, treat and manage ocular disorders, diseases and injuries and systemic diseases that 
manifest in the eye. The American Optometric Association is a federation of state, student, and armed 
forces optometric associations. Through these affiliations, the  AOA serves members consisting of 
optometrists, students of optometry, paraoptometric assistants and technicians. The AOA and its affiliates 
work to provide the public with quality vision and eye  care.  
Centers for Disease Control and Prevention (CDC): The Centers for Disease Control and Prevention is a 
national public health institute in the [LOCATION_002]. It is a [LOCATION_002] federal agency, under the Department of Health and Human Services, and is headquartered in Atlanta, Georgia.  
COVID -19: Current outbreak of respi[INVESTIGATOR_19538] a novel coronavirus. The virus has been 
named “SARS -CoV-2” and the disease it causes has been named “Coronavirus Disease 2019” (COVID- 
19). 
Clinical Study: Voluntary research studies conducted in people and designed to  answer specific 
questions about the safety or effectiveness of drugs, vaccines, other therapi[INVESTIGATOR_014], or new ways of using existing treatments. May also be called clinical trials, studies, research, trials, or protocols.  
Clinical Study Site: Location where a c linical study is conducted, such as a doctor’s office, university, or 
laboratory. Clinical studies are conducted by [CONTACT_35583](s) responsible for the conduct of the clinical study at a study site. If a study is conducted by a team of individuals, the 
Investigator is the responsible leader of the team and may be called the Principal Investigator.  
Clinical Operations Manager (COM): The [COMPANY_012] Vision Care (JJVCI) individual 
responsible for the overall management of a clinical t rial. 
CR-6480, v5.0
 
Page 205 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: 5 
 
 
Monitor: An individual designated to oversee the progress of a clinical study and ensure that it is 
conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures 
(SOPs), Good Clinical Practice (GCP), and applicable regulatory requirements.  
 
Medical Safety Officer (MSO): Physician who has primary accountability in their product portfolio for product health and safety, and who serves as an independent medical voice for patient safety.  
 
Safety Management Team (SMT): A cross -functional, collaborative team responsible for review, 
assessment and evaluation of medical safety data arising from any source throughout the product life 
cycle.  
 
4.[ADDRESS_308352]  the health,  
safety and well -being of participants and site staff. If, at any time, a participant’s safety is considered to be 
at risk, study interventio n will be discontinued, and study follow -up will be conducted as outlined in the  
protocol.  
 
During the COVID -19 pandemic,  the additional  risks  listed  below need  to be considered  for study participants 
and study personnel:  
 
Additional Risks Related to the COVID -19 Pandemic:  
• The possible transmission of the Coronavirus infection and consequent complications, beyond the 
risk of adverse events due to the investigational device and/or  procedures.  
• The risk may be higher in an optometric clinical study becaus e of the close contact [CONTACT_93950] (since the investigator must make the measurements close to the subject’s face) and, in addition the need for multiple 
follow -up visits/exams which may expose the subject to other patients and/or healthcare 
professionals who might be transmitting the virus, even if they do not have  symptoms.  
• Potential disruptions to the study may be necessary due to current or future pandemic -related 
emergency r estrictions, which may lead to delays in scheduled follow -up visits.  
• Subjects experiencing an adverse event related to contact [CONTACT_126134] -[ADDRESS_308353] contracted COVID -19 during participation in a study, he/she will be 
discontinued from the study and followed until COVID -19 Adverse Event (AE) resolution.  
 
To help minimize the above potential risks, JJVCI recommend reviewing/complying with local, state, 
and governmental guidance fo r COVID -19 risks.  
 
JJVCI will provide the following study specific documents with language pertaining to COVID- 19 risks:  
 
4.1.1 Informed Consent : 
 
Will include information concerning the study -associated risks related to the COVID -19 pandemic 
in bold font and/or  boxed on the first page of the Informed Consent document:  
CR-6480, v5.0
 
Page 206 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: 5 
 
 
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS) PANDEMIC  
 
It is important to note that this study will be conducted, at least in part, during the COVID -[ADDRESS_308354] for you. This is particularly important for this 
study due, in part, to the closeness of the doctor during the study exam inations.  
 
The potential effects of the disease are not fully known, at this time, and may include long -term serious health 
consequences. In severe cases, this may result in hospi[INVESTIGATOR_5478]/or death. Based on current knowledge from 
the Centers for Disease Control and Prevention (CDC), those at high -risk for severe illness from COVID -19 include 
older adults and people with underlying medical conditions.  
 
During this study, all appropriate measures will be taken to minimize risks including the use of pers onal 
protective equipment such as masks and gloves, as well as proper sanitization. This is in conformance to 
guidance from the CDC, local health departments, and the state and county in which the study doctor’s office is located. However, these measures may not completely eliminate the risks associated with contracting COVID -19. 
 
If you are found to have contracted COVID -19 or feel ill with flu -like symptoms during participation in the study, 
you will not be permitted to continue in- office study follow- up visits, but you will receive instructions and your 
condition will be monitored by [CONTACT_35586]/or study staff.  
 
4.1.[ADDRESS_308355]  (Attachment -B): 
 
Will include COVID -[ADDRESS_308356] JJVCI clinical 
studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Principal Investigator [INVESTIGATOR_5972]/sign the study specific checklist prior to the Site Initiation Meeting.  
 
 
4.1.3 Protocol Compliance Investigator(s) Signature [CONTACT_3490]:  
 
Will inclu de a statement indicating that the Principal Investigator (PI) agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s for COVID -[ADDRESS_308357]  read  the suggested  guidance  provided by [CONTACT_253461] -19 risk mitigation, 
(COVID -19 Work Instruction in the Appendix of this protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID- 19 risks.  
 
4.1.4 Study Site Initiation Training Slides:  
 
Will include suggestions to help mitigate potential transmission of COVID -19. Suggestions may 
include maintaining social distancing in the clinical site by [CONTACT_35587], wearing proper PPEs, frequent disinfection, and installing shields on the slit lamp and other 
applicable equipment.  
 
5.[ADDRESS_308358]  VISITS 
 
Potential disruptions to the study may be necessary due to current or future pandemic -related emergency 
restrictions. Possible disruption of the study as a result of COVID- 19 control measures may lead to delays in 
scheduled follow -up visits.  
 
Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID -[ADDRESS_308359]’s concerns or fears about COVID -[ADDRESS_308360]  during  remote  
assessments may include:  
CR-6480, v5.0
 
Page 207 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: [ADDRESS_308361] the sponsor’s 
responsible medical monitor to discuss initial plans for study intervention and follow -up. The medical 
monitor will notify the Safety Management Team of any subject(s) that have reported “COVID -19”, 
“Asymptomatic COVID -19”, or “Suspected COVID -19” adverse events within [ADDRESS_308362] as a result of the COVID -19 pan demic will be summarized in the 
clinical study report.  
 
COVID -19 screening procedures that may be mandated by [CONTACT_35588].  
 
Monitoring Visits  
 
When  on-site monitoring by [CONTACT_93953],  the sponsor’s  site monitor  will contact  [CONTACT_19614]. In such cases, on -site monitoring visits will resume when feasible, with 
increased frequency to address the source data verification  backlog.  
 
Even  with  staffing  limitations  during  this COVID -[ADDRESS_308363] process. When conditions permit, 
all parties  invol ved in this clinical trial should  communicate  relevant  information  in a timely  manner  so 
that all relevant parties remain sufficiently  informed.  
 
6.1.1 Study Site Initiation: 
 
During the period that this Work Instruction is in effect, Site Initiation Meetings and training of study site staff will be conducted remotely. The JJVCI study team will conduct training via Skype, Zoom, Microsoft  Teams  or similar  software as well as utilize  online  training materials,  as applicable. 
Study site training will be documented utilizing Site Initiation Report  
per Study Site Initiation  
 
On-site visits  may  be considered  when,  for example,  hands -on training or evaluation  of site facilities 
is required. While on site, the Clinical Research Associate (CRA) will follow all local, state, and governmental  policies  for COVID -19 Risk Mitigation,  including social distancing,  wearing  of PPE, etc. 
as applicable for the location of the study  site.  
 
6.1.2 Interim Monitoring Visits  (if applicable):  
 
During the period that this Work Instruction is in effect, Interim Monitoring On -site visits will be 
kept  to a minimum  and include  only  those  tasks  that the CRA cannot  perform remotely  (e.g.,  source 
document verification, test article reconciliation, etc.).  
 
To ensure  data  integrity  during  the conduct  of all JJVC  studies,  clinical study  teams  will follow  the 
study specific Clinical Monitoring Plan  
 
While on site, the CRA will follow all local, state,  and governmental policies for COVID- 19 Risk 
Mitigation, including social distancing, wearing of PPE, etc. as applicable for the location of the study site.  
CR-6480, v5.0
 
Page 209 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: 5 
 
 
6.1.3 Study Site Closure:  
 
During the period  that this Work  Instruction  is in effect,  the duration  of the Study Site Closure  Visit 
will be limited to tasks that the CRA cannot perform remotely (e.g., source document verification, 
test article final reconciliation and return,  etc.).  
CR-6480, v5.0
 
Page 210 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Joh nson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: 5 
 
 
Attachment A: Study Site Correspondence  
 
XXXX XX, 2020  
 
 
Re: COVID -19 Mitigation Plan, <<CR -xxxx/protocol title>>  
 
 
Dear <<Principal Investigator>> and Study Team,  
 
Coronavirus (COVID -19) has impacted several communities and business activities over the past several 
months. While we work toward the successful conduct of clinical studies, our commitment continues to be the 
safety of patients, healthcare professionals, and to our c ommunities.  
 
Therefore, we would like to share the following revisions/additions related to the above referenced Johnson & 
Johnson Vision Care company sponsored clinical trial(s) you are currently working on or considering participation 
within.  
 
Protocol:  
 
• Guidelines for COVID -19 Risk Mitigation provided in the Appendix section.  
 
Protocol Signature [CONTACT_3490]:  
 
• Will include a statement indicating the Principal Investigator [INVESTIGATOR_93811], state, and governmental guidelines for COVID -19 risk mitigation.  
 
Informed Consent:  
 
• Will include information concerning the study- associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent  document.  
 
COVID -[ADDRESS_308364] for Clinical Studies:  
 
• Will include COVID -[ADDRESS_308365] with your 
respective [COMPANY_012] clinical study team (Clinical Research Associate (CRA), Lead C RA or Study 
Managers).  
 
Thank you for your continued engagement, collaboration, and dedication to your study subjects during 
this challenging time.  
 
 
Please file this letter in your site file study correspondence.  
CR-6480, v5.0
 
Page 211 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol Johnson 
& Johnson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: 5 
 
 
RESOURCE LINKS  
 
US Resource Links  
 
• OSHA Training  
https://www.osha.gov/SLTC/covid -19/controlprevention.html  
 
Personal Protective Equipment (PPE) Training  
CDC: https://www.cdc.gov/coronavirus/2019- ncov/hcp/using- ppe.html  
 
• I&R Training  
ACUVUE® LensAssist: https://www.acuvue.com/lensassist  
 
• Clinic Preparedness  Guides  
CDC: https://www.cdc.gov/coronavirus/2019- ncov/hcp/clinic- preparedness.html  
AOA: https://aoa.uberflip.com/i/1240437- aoa-guidance -for-re-opening -practices -covid·19/1?m4=  
American Optometric Associ ation: https://www.aoa.org/optometry -practice -reactivation -
preparedness - guide  
 
• ln-Office Disinfection of Multi- Patient Use Diagnostic Contact  [CONTACT_93957]://www.gpli.info/wp -content/uploads/2020/03/2020- 01-15-in-office -disinfecting -of-diagnostic - 
lenses.pdf  
 
OUS Resource Links  
 
• Updates on local regulations in Hong Kong 
https://www.coronavirus.gov hk/eng/index.html  
 
• Resumption of optical services in England: Letter from Matt Neligan and Poonam Sharma  
https:// www.england.nhs.uk/coronavirus/wp- content/uploads/sites/52/2020/04/C0601- reopening- of-optical - 
services -letter -17-june-2020.pdf  
 
• NHS Optical  Letter  
https://www.england.nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0127- optical- letter -1-april - 
2020.pdf  
 
• The College of Optometrists primary eye care COVID -19 guidance: Red  phase  
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavirus -covid -19-guidance - 
for-optometrists.html  
 
• The College of Optometrists COVID -19: College updates  
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavirus -2019-advice- for- 
optometrists.html#CollegeGuidelines  
 
• Infection Control Guidelines. (n.d.). Retrieved from Canadian Associa tion Of Optometrists: 
https://opto.ca/sites/default/files/resources/documents/infection_control_guidelines_2016.pdf  
• Infection prevention and control for COVID -19: Interim guidance for outpatient and ambulatory care 
settings. (2020, May 23 May). Retrieved from Government of Canada: https:// www.canada.ca/en/public-  
health/services/diseases/2019 -novel -coronavirus -infection/guidance -documents/interim -guidance - 
outpatient -ambula tory-care- settings html 
CR-6480, v5.0
 
Page 214 of 216
JJVC CONFIDENTIAL

Clinical Study Protocol J ohnson 
& Johnson Vision Care, Inc.  
Guidelines for COVID -19 Risk Mitigation  Title:   
 Document  Type:   
 
Document  Number:   Revision Number: 5 
 
 
• Information for Members  On Coronavirus  (COVID- 19). (n.d.). Retrieved  from  Canadian  Association  Of 
Optometrists: 
https://opto.ca/sites/default/files/resources/documents/information_for_members_on_coronavirus.pdf  
• Coronavirus (COVID -19) resources for health professionals, including aged care providers, pathology 
providers and health care managers. (2020,  September 24). Retrieved from Australian Government 
Department of  Health: 
https:// www.health.gov.au/resources/collections/coronavirus -covid -19-resources -for-health -professionals - 
including- aged -care -providers -pathology -providers -and-health -care -managers  
 
• Environmental Cleaning and Disinfection Principles for COVID -19. (n.d.). Retrieved from Australian 
Government Department of Health: 
https:// www health.gov.au/sites/default/files/documents/2020/03/environmental -cleaning -and-disinfection-  
principles -for-covid- 19.pdf  
• Infection control guidelines and advice. (n.d.). Retrieved from Optometry Australia : 
https ://www.optometry.org.au/practice -professional -support/coronavirus -covid -19-what -optometrists -need- to-
know/covid -19-clinical- advice/infection -control -guidelines -and-advice/  
CR-6480, v5.0
 
Page 215 of 216
JJVC CONFIDENTIAL

  
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_93962]: CR -[ADDRESS_308366] Lenses With UV/HEV -Filter on 
Visual Function 
 
Version and Date: 5.[ADDRESS_308367] this study according to ISO [ZIP_CODE]:2020,1 the Declaration of Helsinki,2 
[LOCATION_002] (US) Code of Federal Regulations (CFR),3 and the pertinent individual country 
laws/regulations and to comply with its obligations, subject to ethical and safety 
considerations. The Principal Investigator [INVESTIGATOR_19539], including Sub- Investigators adhere to all GCP guidelines regarding clinical trials 
during and after study completion. 
 
I will assure that no deviation from or changes to the protocol will take place without prior agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.  
 
All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training. 
 
I agree to ensure that all clinical site personnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitments. 
 
I shall not disclose the information contained in this protocol or any results obtained from  this 
study without written  authorization. 
 
I have read the suggested guidance provided by [CONTACT_19610] -19 risk 
mitigation,  (COVID-19 Work  Instruction  in the Appendix of this protocol). I agree to conduct 
this study in compliance with local, state, governmental guidance for COVID-19 risks.  
 
Principal  
Investigator:      
   
[INVESTIGATOR_253415] (Printed)   
Institution/Site:      
Institution/Site Name   
[CONTACT_16277]/Site Address   
 
CR-6480, v5.0
 
Page 216 of 216
JJVC CONFIDENTIAL
